Cover
Cover - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Feb. 22, 2022 | |
Cover [Abstract] | ||
Document Type | 10-K | |
Document Annual Report | true | |
Document Period End Date | Dec. 31, 2021 | |
Current Fiscal Year End Date | --12-31 | |
Document Transition Report | false | |
Entity File Number | 001-38701 | |
Entity Registrant Name | SI-BONE, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 26-2216351 | |
Entity Address, Address Line One | 471 El Camino Real | |
Entity Address, Address Line Two | Suite 101 | |
Entity Address, City or Town | Santa Clara | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95050 | |
City Area Code | 408 | |
Local Phone Number | 207-0700 | |
Title of 12(b) Security | Common Stock, par value $0.0001 per share | |
Trading Symbol | SIBN | |
Security Exchange Name | NASDAQ | |
Entity Well-known Seasoned Issuer | Yes | |
Entity Voluntary Filers | No | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
ICFR Auditor Attestation Flag | true | |
Entity Shell Company | false | |
Entity Public Float | $ 1,000 | |
Entity Common Stock, Shares Outstanding | 33,840,570 | |
Documents Incorporated by Reference | Portions of the Registrant’s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Report . | |
Entity Central Index Key | 0001459839 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | FY | |
Amendment Flag | false | |
Entity Filer Category | Large Accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Small Business | true |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2021 | |
Audit Information [Abstract] | |
Auditor Firm ID | 238 |
Auditor Name | PricewaterhouseCoopers LLP |
Auditor Location | San Jose, California |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 63,419 | $ 53,581 |
Short-term investments | 83,560 | 142,851 |
Accounts receivable, net of allowance for credit losses of $264 and $263, respectively | 14,246 | 13,611 |
Inventory | 11,498 | 5,633 |
Prepaid expenses and other current assets | 3,143 | 2,565 |
Total current assets | 175,866 | 218,241 |
Property and equipment, net | 8,992 | 4,527 |
Operating lease right-of-use assets | 5,248 | 0 |
Other non-current assets | 400 | 374 |
TOTAL ASSETS | 190,506 | 223,142 |
CURRENT LIABILITIES | ||
Accounts payable | 3,198 | 3,271 |
Accrued liabilities and other | 12,353 | 10,199 |
Operating lease liabilities, current portion | 1,339 | 0 |
Total current liabilities | 16,890 | 13,470 |
Long-term borrowings | 34,973 | 39,455 |
Operating lease liabilities, net of current portion | 4,166 | 0 |
Other long-term liabilities | 57 | 854 |
TOTAL LIABILITIES | 56,086 | 53,779 |
Commitments and contingencies (Note 6) | ||
STOCKHOLDERS’ EQUITY | ||
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock, $0.0001 par value; 100,000,000 shares authorized; 33,674,085 and 32,583,220 shares issued and outstanding, respectively | 3 | 3 |
Additional paid-in capital | 429,914 | 408,113 |
Accumulated other comprehensive income | 352 | 524 |
Accumulated deficit | (295,849) | (239,277) |
TOTAL STOCKHOLDERS’ EQUITY | 134,420 | 169,363 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 190,506 | $ 223,142 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Allowance for credit losses | $ 264 | $ 263 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock issued (in shares) | 0 | 0 |
Preferred stock outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock issued (in shares) | 33,674,085 | 32,583,220 |
Common stock outstanding (in shares) | 33,674,085 | 32,583,220 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | ||
Revenue | $ 90,152 | $ 73,387 |
Cost of goods sold | 10,428 | 8,902 |
Gross profit | 79,724 | 64,485 |
Operating expenses: | ||
Sales and marketing | 93,884 | 73,790 |
Research and development | 12,441 | 9,459 |
General and administrative | 25,069 | 19,803 |
Total operating expenses | 131,394 | 103,052 |
Loss from operations | (51,670) | (38,567) |
Interest and other income (expense), net: | ||
Interest income | 186 | 1,097 |
Interest expense | (5,365) | (6,101) |
Other income (expense), net | 277 | (126) |
Net loss | (56,572) | (43,697) |
Other comprehensive income (loss): | ||
Unrealized loss of marketable securities | (31) | (59) |
Changes in foreign currency translation | (141) | 119 |
Comprehensive loss | $ (56,744) | $ (43,637) |
Net loss per share, basic (in USD per share) | $ (1.71) | $ (1.50) |
Net loss per share, diluted (in USD per share) | $ (1.71) | $ (1.50) |
Weighted-average number of common shares used to compute basic and diluted net loss per share, basic (in shares) | 33,145,930 | 29,059,171 |
Weighted-average number of common shares used to compute basic and diluted net loss per share, diluted (in shares) | 33,145,930 | 29,059,171 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income | Accumulated Deficit |
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2019 | 25,163,803 | ||||
Stockholders' equity, beginning balance at Dec. 31, 2019 | $ 63,008 | $ 3 | $ 258,121 | $ 464 | $ (195,580) |
Increase (Decrease) in Stockholders' Equity | |||||
Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs (in shares) | 6,613,560 | ||||
Issuance of common stock from public offerings, net of underwriting discounts, commissions and offering costs | $ 134,616 | 134,616 | |||
Issuance of common stock upon exercise of stock options, net of shares withheld (in shares) | 323,701 | 323,701 | |||
Issuance of common stock upon exercise of stock options, net of shares withheld | $ 1,463 | 1,463 | |||
Issuance of common stock related to employee stock purchase plan (in shares) | 137,377 | 137,377 | |||
Issuance of common stock related to employee stock purchase plan | $ 1,915 | 1,915 | |||
Issuance of common stock upon vesting of restricted stock units (in shares) | 344,779 | ||||
Issuance of common stock upon vesting of restricted stock units | 0 | ||||
Stock-based compensation | 11,927 | 11,927 | |||
Vesting of early exercised stock options | 71 | 71 | |||
Foreign currency translation | 119 | 119 | |||
Net unrealized gain (loss) on marketable securities | (59) | (59) | |||
Net loss | (43,697) | (43,697) | |||
Stockholders' equity, ending balance (in shares) at Dec. 31, 2020 | 32,583,220 | ||||
Stockholders' equity, ending balance at Dec. 31, 2020 | $ 169,363 | $ 3 | 408,113 | 524 | (239,277) |
Increase (Decrease) in Stockholders' Equity | |||||
Issuance of common stock upon exercise of stock options, net of shares withheld (in shares) | 369,375 | 369,375 | |||
Issuance of common stock upon exercise of stock options, net of shares withheld | $ 2,565 | 2,565 | |||
Issuance of common stock related to employee stock purchase plan (in shares) | 147,295 | 147,295 | |||
Issuance of common stock related to employee stock purchase plan | $ 2,343 | 2,343 | |||
Issuance of common stock upon vesting of restricted stock units (in shares) | 574,195 | ||||
Issuance of common stock upon vesting of restricted stock units | 0 | ||||
Stock-based compensation | 16,866 | 16,866 | |||
Vesting of early exercised stock options | 27 | 27 | |||
Foreign currency translation | (141) | (141) | |||
Net unrealized gain (loss) on marketable securities | (31) | (31) | |||
Net loss | (56,572) | (56,572) | |||
Stockholders' equity, ending balance (in shares) at Dec. 31, 2021 | 33,674,085 | ||||
Stockholders' equity, ending balance at Dec. 31, 2021 | $ 134,420 | $ 3 | $ 429,914 | $ 352 | $ (295,849) |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities | ||
Net loss | $ (56,572) | $ (43,697) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Stock-based compensation | 16,866 | 11,927 |
Depreciation and amortization | 2,086 | 1,130 |
Bad debt expense | 14 | 234 |
Accretion of discount on marketable securities | 1,294 | 115 |
Realized gain on marketable securities | 0 | (46) |
Amortization of debt issuance costs | 288 | 292 |
Loss on extinguishment of debt | 1,848 | 1,534 |
Loss on sale and disposal of property and equipment | 399 | 376 |
Changes in operating assets and liabilities | ||
Accounts receivable | (569) | (2,186) |
Inventory | (5,784) | (274) |
Prepaid expenses and other assets | (594) | (136) |
Accounts payable | (532) | 835 |
Accrued liabilities and other | 1,723 | (766) |
Net cash used in operating activities | (39,533) | (30,662) |
Cash flows from investing activities | ||
Maturities of marketable securities | 159,990 | 104,716 |
Sales of marketable securities | 0 | 14,095 |
Purchases of marketable securities | (102,021) | (179,166) |
Purchases of property and equipment | (6,389) | (2,561) |
Net cash (used in) provided by investing activities | 51,580 | (62,916) |
Cash flows from financing activities | ||
Proceeds from follow-on public offering, net of underwriting discounts, commissions and offering costs | 0 | 134,616 |
Proceeds from debt financing | 35,000 | 45,297 |
Repayments of debt financing | (41,000) | (45,297) |
Payments of debt issuance costs | (111) | (750) |
Payments of prepayment penalty and lender fees | (508) | (843) |
Proceeds from the exercise of common stock options | 2,565 | 1,463 |
Proceeds from issuance of common stock under employee stock purchase plan | 2,343 | 1,915 |
Net cash (used in) provided by financing activities | (1,711) | 136,401 |
Effect of exchange rate changes on cash and cash equivalents | (498) | 323 |
Net increase in cash and cash equivalents | 9,838 | 43,146 |
Cash and cash equivalents at | ||
Beginning of year | 53,581 | 10,435 |
End of year | 63,419 | 53,581 |
Supplemental disclosure of cash flow information | ||
Cash paid for interest | 3,230 | 4,276 |
Supplemental disclosure of non-cash information | ||
Vesting of early exercised stock options | 27 | 71 |
Unpaid purchases of property and equipment | $ 509 | $ 26 |
The Company and Nature of Busin
The Company and Nature of Business | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
The Company and Nature of Business | The Company and Nature of Business SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The Company introduced its first generation iFuse implant in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world. In the first quarter of 2020, the Company received $63.0 million of net proceeds from its first follow-on public offering of 4,300,000 shares of the Company's common stock, of which 2,490,053 shares were offered and sold by the Company, and the exercise of underwriter's option to purchase from the Company an additional 645,000 shares of the Company's common stock, at a public offering price of $21.50 per share. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the selling stockholders on a pro-rated basis. Public offering cost of $0.4 million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $0.2 million allocated to selling of shares by the selling stockholders was recognized as transaction costs within general and administrative expenses on the consolidated statements of operations in the year ended December 31, 2020. In October 2020, the Company received $71.6 million of net proceeds from its second follow-on public offering of shares of the Company's common stock, of which 3,000,000 shares were offered and sold by the Company, and the exercise of underwriter's option to purchase from the Company an additional 478,507 shares of the Company's common stock, at a public offering price of $22.00 per share. In addition to the shares sold by the Company in this second follow-on offering, the selling stockholder sold 190,053 shares of the Company's common stock previously held by the selling stockholder at a price to the public of $22.00 per share. The Company did not receive any proceeds from the sale by the selling stockholder. Risks and Uncertainties The Company is subject to continuing risk and uncertainties as a result of the COVID-19 pandemic, and is closely monitoring the impact of the pandemic on all aspects of its business, including the impacts on its customers, patients that would benefit from procedures involving the Company's products, employees, suppliers, vendors, business partners and distribution channels. Economies worldwide continue to be negatively impacted by the COVID-19 pandemic, in particular with recurrent mutations of the virus, despite advances in vaccines, and the Company anticipates these disruptions will continue. While the Company has not experienced material disruptions to its supply chain to date, certain of its third-party suppliers have faced delays, product shortages and rising costs resulting from disruptions in the global supply chain, primarily related to the instruments. As a result, the Company is continuing to work closely with its manufacturing partners and suppliers, as well as determining alternative sourcing strategies to enable the Company to source key components and maintain appropriate inventory levels to meet customer demand. As such the Company's future results of operations and liquidity could be adversely impacted by a variety of factors related to the COVID-19 pandemic, including those discussed in the section entitled "Risk Factors" in this report. As of the date of issuance of these consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations remains uncertain. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period . Significant accounting estimates and management judgments reflected in the consolidated financial statements primarily includes the fair value of stock options. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates. Segments The Company's chief operating decision makers are the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”). The CEO and the CFO review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company derives substantially all of its revenue from sales to customers in the U.S. Revenue by geography is based on billing address of the customer. International revenue accounted for less than 10% of the total revenue during the periods presented. Long-lived assets held outside the U.S. are immaterial. Following table summarizes the Company's revenue by geography: Year Ended December 31, 2021 2020 (in thousands) United States $ 82,739 $ 68,118 International 7,413 5,269 $ 90,152 $ 73,387 Foreign Currency The Company’s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses from foreign currency translation are recorded as a component of accumulated other comprehensive income (loss). Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company’s cash and marketable securities are deposited with financial institutions in the U.S. and in Europe. The majority of the Company’s cash and marketable securities are deposited with a single financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities. The Company’s revenue and accounts receivable are spread across a large number of customers, primarily in the U.S., and no customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented. Fair Value of Financial Instruments Carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy as defined below. The carrying value of the Company’s long-term debt also approximates fair value based on management’s estimation that a current interest rate would not differ materially from the stated rate. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. Cash and Cash Equivalents The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents. Marketable Securities The Company's marketable securities primarily consist of investments in money market funds, U.S. treasury securities, corporate bonds and commercial paper. All of the Company's marketable securities are available-for-sale and are classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short term investments are securities that original or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities that original or remaining maturity is more than twelve months. All marketable securities are recorded at their estimated fair value. When the fair value of a security is below its amortized cost, the amortized cost will be reduced to its fair value if it is more likely than not that the Company will be required to sell the potentially impaired security before recovery of its amortized cost basis, or the Company has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost over the fair value of the security. An allowance for credit losses for the excess of amortized cost over the expected cash flows is recorded in other income, net in the consolidated statements of operations. Impairment losses that are not credit-related are included in accumulated other comprehensive income (loss) in stockholders’ equity. Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount, net of allowances for credit losses for any potential uncollectible amounts. The allowance for credit losses is based on our assessment of the collectability of accounts. Management regularly reviews the adequacy of the allowance for credit losses on a collective basis by considering the age of each outstanding invoice, each customer’s expected ability to pay and collection history, current market conditions, and reasonable and supportable forecasts of future economic conditions to determine whether the allowance is appropriate. Accounts receivable are written-off and charged against an allowance for credit losses when the Company has exhausted collection efforts without success. For the years ended December 31, 2021 and 2020, the allowance for credit losses activity was not significant. The movement in the allowance for credit losses was as follows: Year ended December 31, 2021 2020 (in thousands) Balance at beginning of year $ 263 $ 238 Provision 14 234 Write-offs (13) (209) Balance at end of year $ 264 $ 263 Inventory Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the purchase costs on a first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows: Computer and office equipment 3 – 5 years Machinery and equipment 3 – 5 years Furniture and fixtures 7 years Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets (or asset group) may not be fully recoverable. Whenever events or changes in circumstances suggest that the carrying amount of long-lived assets may not be recoverable, the Company estimates the future cash flows expected to be generated by the assets (or asset group) from its use or eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Significant management judgment is required in the grouping of long-lived assets and forecasts of future operating results that are used in the discounted cash flow method of valuation. Through December 31, 2021 and 2020, the Company has not experienced impairment losses on its long-lived assets. Leases The Company determines if an arrangement is a lease at inception. The classification of leases is evaluated at commencement and, as necessary, at modification. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheets. The Company does not have any material finance leases in any of the periods presented. Under Accounting Standards Update ("ASU") 2016-02, Leases Topic 842 ("Topic 842"), operating lease expense is recognized on a straight-line basis over the term of the lease. Variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The lease term represents the non-cancelable period of the lease. For certain leases, the Company has an option to extend the lease term. These renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options. The Company elected certain practical expedients under Topic 842 which are: (i) to not record leases with an initial term of twelve months or less on the balance sheet; (ii) to combine the lease and non-lease components in determining the lease liabilities and right-of-use assets, and (iii) to carry forward prior conclusions about lease identification and classification. The Company’s lease contracts do not provide an implicit borrowing rate; hence the Company determined the incremental borrowing rate based on information available at lease commencement to determine the present value of lease liability. The Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company uses its headquarters in the U.S. ("parent entity")’s incremental borrowing rates as the treasury operations are managed centrally by the parent entity. Revenue Recognition The Company’s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the U.S. and Europe. The Company adopted the revenue standard in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) effective for the fiscal year ended December 31, 2019. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. Under the revenue recognition standard, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at the hospital or medical facilities, the Company continues to recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. This represents the majority of the Company's consolidated revenue. The Company also generates a small portion of revenue from the sale of products through distributors and to certain hospital or medical facilities where the products are ordered in advance of a procedure. The performance obligation is the delivery of the products and therefore, revenue is recognized upon shipment to the customers, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there had been no significant price discounts. Sales prices are specified in either the customer contract or agreed price list, which is executed prior to the transfer of control to the customer. For certain hospitals and medical facilities, the Company has agreements in place consists of either a master services agreement or an agreed price list, which defines the terms and conditions of the arrangement, including the pricing information, payment terms and pertinent aspects of the relationship between the parties. The Company also has agreements in place with its distributors, which include standard terms that do not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor’s payment obligation. The Company's standard payment terms are generally net 30 to 90 days. Shipping and Handling Costs Shipping and handling costs are treated as fulfillment costs, which are expensed as incurred and are included in cost of goods sold. Costs to Obtain Customer Contracts Sales commissions and related expenses are considered incremental and recoverable costs of acquiring customer contracts. The Company’s sales commissions paid to its sales representatives are generally based on the surgeries performed. The Company applied the practical expedient that permits an entity to expense the cost to obtain a contract as incurred when the expected amortization is one year or less. The period of benefit is concurrent with when the Company recognizes its revenue and as such, the Company recognizes sales commission as expense when incurred. Warranty The Company has a warranty program that provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a one-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the one-year period following an original procedure where an implant is not required. The warranty is not priced or sold separately and is intended to safeguard the customer against defects and it does not provide incremental service to the customer. As such, it is considered an assurance type warranty and is not accounted as a service type warranty, which could represent a separate performance obligation. The Company accounts for these one-time credits as sales reserves and is included in accrued liabilities and other in the consolidated balance sheets. Sales and warranty reserves from the warranty program were immaterial as of December 31, 2021 and 2020. Research and Development Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company’s product which primarily include: (1) employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; (2) external research and development expenses; and (3) other expenses, which include direct and allocated expenses for facilities and other costs. Advertising Expenditures The cost of advertising is expensed as incurred and is included under sales and marketing expense in the consolidated statements of operations. Advertising expenses were $1.2 million and $0.3 million for the year ended December 31, 2021 and 2020, respectively. Loss Contingency The Company is subject to various potential loss contingencies arising in the ordinary course of business. From time to time, the Company may be involved in certain proceedings, legal actions and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within the Company's control and may not be known for prolonged periods of time. In some actions, the claimants may seek damages, as well as other relief, including injunctions which may prohibit the Company to engage in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. The Company records a liability in the consolidated financial statements when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. Stock-Based Compensation The Company applies the fair value recognition provisions of stock-based compensation. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised. The Company estimates the grant date fair value of stock options using the Black-Scholes option valuation model. The model requires management to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividends. A number of these assumptions are subjective, and their determination generally require judgment. • Expected Term - The expected term represents the period that the share-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term as permitted by the guidance since the Company has no sufficient historical exercise patterns to estimate the expected life. The simplified method is calculated as the average of the time to vesting and the contractual life of the options. • Expected Volatility - The expected volatility is measured using the historical daily changes in the market price of the Company's common stock over a period consistent with the expected term. • Risk-Free Interest Rate - The risk-free interest rate is based on the U.S. Treasury zero coupon issued in effect at the time of grant for periods corresponding with the expected term of the option. • Dividend Yield - The Company has not paid any dividends and has no current plans to pay dividends on its common stock. As such, the Company uses expected dividend yield of zero. The fair value of the restricted stock unit (“RSU”) grant is based on the market price of the Company’s common stock on the date of grant. Prior to the Company's initial public offering (“IPO”), the fair value of the shares of the Company's common stock has historically been determined by its Board of Directors since there were no public market information available for the Company's common stock. The estimated fair value of the Company's common stock was determined at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation . Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the Nasdaq Global Market on the date of grant. Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned. In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date. Income Taxes The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company recognizes uncertain tax positions when it meets a more-likely-than-not threshold. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as income tax expense. Net Loss per Share of Common Stock The Company calculates basic and diluted net loss per common share attributable to shareholders i n conformity with the two-class method required for companies with participating securities. The Company considers all ea rly exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the early exercised stock options as the holders do not have a contractual obligation to share in losses. Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, restricted stock units and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods. Comprehensive Loss Comprehensive loss represents all changes in the stockholders’ equity except those resulting from distributions to stockholders. The Company’s unrealized foreign currency translation income (losses) and unrealized gains (losses) on marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss. Warrants The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i) indexed to the entity’s own stock and (ii) classified in the stockholders’ equity section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made. Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which requires that lessee's recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet. In July 2018, the FASB issued ASU 2018-10 and ASU 2018-11, which provides clarification on the narrow aspects of the guidance and provide an additional transition method to adopt the new leases standard. In March 2019, the FASB issued ASU 2019-01, which provides clarification on implementation issues associated with adopting ASU 2016-02. The new leases standard must be adopted using a modified retrospective transition method and allows for the application of the new guidance at the beginning of the earliest comparative period presented or at the adoption date. In November 2019, the FASB issued ASU 2019-10, which revised the mandatory effective dates of the new leases standard. Further, due to the impact of the COVID-19, in June 2020, the FASB issued ASU 2020-05 to further defer the effective date for one year for entities in the “all other” categories. In the fourth quarter of 2021, the Company adopted Topic 842 for leases, using the modified retrospective method, applying Topic 842 to all leases existing at the date of initial application. The Company elected to use the effective date of January 1, 2021 as the date of initial application. Under the modified retrospective method, balances and disclosures prior to January 1, 2021 have not been restated. The Company elected certain practical expedients, which among other things, allowed the Company to carry forward prior conclusions about lease identification and classification. The adoption of ASC 842 had a material impact on the consolidated balance sheet as the standard requires the Company to measure and recognize a right of use asset and lease liability. The Company recognized $3.8 million of operating lease liabilities and approximately $3.5 million of operating lease right-of-use assets on the consolidated balance sheet as of January 1, 2021. The difference between the operating lease right-of-use assets and operating lease liabilities represented the existing deferred rent liability balance as of the adoption date of $0.3 million. The adoption of the standard did not have a material impact on the consolidated statement of operations and comprehensive loss and there was no impact to cash from or used in operating, financing or investing activities on the consolidated statement of cash flows. The adoption of ASC Topic 842 had no income tax impact to the financial statements. The Company accounted for the basis differences arising from ASC Topic 842 adoption in deferred taxes which was offset by a valuation allowance. In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). FASB issued ASU 2019-05 in May 2019, ASU 2019-08 and ASU 2019-11 in November 2019 for codification improvements of Topic 326. In November 2019, the FASB issued ASU 2019-10, which defers the effective date of ASU 2016-13 for public companies that are eligible to be smaller reporting companies and all other companies, to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. In February 2020, the FASB issued ASU 2020-02, which provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses. ASU 2016-13 revises the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses for certain financial instruments and financial assets. For trade receivables, the Company is required to estimate lifetime expected credit losses. For available-for-sale debt securities, the Company will recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2021 on a modified retrospective basis. The Company adopted this standard effective for the year ended December 31, 2021, and the adoption did not have a material impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating incomes taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 is effective in 2021 and interim periods within that year and permits for an early adoption. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of the guidance did not have a material impact on its financials statements and related disclosures. Recently Issued Accounting Standards Not Yet Adopted In May 2021, the FASB issued ASU 2021-04 “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” ("ASU 2021-04") which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. An entity should measure the effect of a mo |
Marketable Securities
Marketable Securities | 12 Months Ended |
Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |
Marketable Securities | Marketable Securities All of the Company's marketable securities were available-for-sale and were classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short-term investments are securities that original maturity or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities for which the original maturity or remaining maturity is greater than twelve months. The table below summarizes the marketable securities: December 31, 2021 Amortized Cost Unrealized Gains Unrealized Losses Aggregate Fair Value (in thousands) Money market funds $ 57,829 $ — $ — $ 57,829 Cash equivalents 57,829 — — 57,829 U.S. treasury securities 28,064 — (16) 28,048 Corporate bonds 31,558 4 (23) 31,539 Commercial paper 23,973 — — 23,973 Short-term investments 83,595 4 (39) 83,560 Total marketable securities $ 141,424 $ 4 $ (39) $ 141,389 December 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Aggregate Fair Value (in thousands) Money market funds $ 45,948 $ — $ — $ 45,948 Commercial paper 1,400 — — 1,400 Cash equivalents 47,348 — — 47,348 U.S. treasury securities 74,779 4 (7) 74,776 Corporate bonds 8,940 4 (6) 8,938 Commercial paper 59,137 — — 59,137 Short-term investments 142,856 8 (13) 142,851 Total marketable securities $ 190,204 $ 8 $ (13) $ 190,199 The amortized cost of the Company's available-for-sale securities approximates their fair value. Unrealized losses are generally due to interest rate fluctuations, as opposed to credit quality. However, the Company reviews individual securities that are in an unrealized loss position in order to evaluate whether or not they have experienced or are expected to experience credit losses. As of December 31, 2021 and 2020, unrealized gains and losses from the investments were not material and were not the result of a decline in credit quality. As a result, the Company did not recognize any credit losses related to its investments and that all unrealized gains and losses on available-for-sale securities are recorded in accumulated other comprehensive income (loss) on the consolidated balance sheets during the year ended December 31, 2021 and 2020. The Company elected to present accrued interest receivable separately from short-term and long-term investments on its consolidated balance sheets. Accrued interest rec eivable was $0.3 million as of December 31, 2021 , and was recorded in prepaid expenses and other current assets. The Company also elected to exclude accrued interest receivable from the estimation of expected credit losses on its marketable securities and reverse accrued interest receivable through interest income (expense) when amounts are determined to be uncollectible. The Company did not write off any accrued interest receivable during the twelve months ended December 31, 2021 and 2020. |
Fair Value Measurement
Fair Value Measurement | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurement | Fair Value Measurement Carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company’s long-term debt also approximates fair value based on management’s estimation that a current interest rate would not differ materially from the stated rate. There were no other financial assets and liabilities that requires fair value hierarchy measurements and disclosures for the periods presented. The table below summarizes the fair value of the Company’s marketable securities measured at fair value on a recurring basis based on the three-tier fair value hierarchy: December 31, 2021 Level 1 Level 2 Level 3 Total (in thousands) Marketable securities Money market funds $ 57,829 $ — $ — $ 57,829 U.S. treasury securities 28,048 — — 28,048 Corporate bonds — 31,539 — 31,539 Commercial paper — 23,973 — 23,973 Total marketable securities $ 85,877 $ 55,512 $ — $ 141,389 December 31, 2020 Level 1 Level 2 Level 3 Total (in thousands) Marketable securities Money market funds $ 45,948 $ — $ — $ 45,948 U.S. treasury securities 74,776 — — 74,776 Corporate bonds — 8,938 — 8,938 Commercial paper — 60,537 — 60,537 Total marketable securities $ 120,724 $ 69,475 $ — $ 190,199 |
Balance Sheet Components
Balance Sheet Components | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Balance Sheet Components | Balance Sheet Components Inventory As of December 31, 2021 and 2020, inventory consisted entirely of finished goods. Property and Equipment, net : December 31, 2021 December 31, 2020 (in thousands) Machinery and equipment $ 10,573 $ 6,342 Construction in progress 3,657 1,692 Computer and office equipment 916 714 Leasehold improvements 503 503 Furniture and fixtures 309 233 15,958 9,484 Less: Accumulated depreciation and amortization (6,966) (4,957) $ 8,992 $ 4,527 As of December 31, 2021, construction in progress pertains to cost of individual components of a custom instrument set used for surgical placement of the Company's products that have not yet been placed into service of $3.3 million and construction costs related to the lease in Santa Clara of $0.4 million. Depreciation expense was $2.1 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively. Accrued Liabilities and Other : December 31, 2021 December 31, 2020 (in thousands) Accrued compensation and related expenses $ 10,055 $ 9,175 Accrued professional services 995 511 Others 1,303 513 $ 12,353 $ 10,199 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Operating Leases The Company has a non-cancelable operating lease for an office building space, located in Santa Clara, California which expires in May 2025. The Company also has non-cancelable operating leases for its office building spaces in Gallarate, Italy and Knaresborough, United Kingdom, which expire in August 2027 and December 2025, respectively. Effective April 30, 2021, the Company terminated its office lease in Mannheim, Germany, and commenced a new lease that can be terminated at any time with six months written notice to the landlord. Further, the Company also leases vehicles under operating lease arrangements for certain of its personnel in Europe which expire at various times throughout 2022 to 2027. In August 2021, the Company signed a new lease for 19,534 square feet of research and development and warehouse space in Santa Clara, California. The term of the new lease commenced on November 1, 2021 and will terminate on October 31, 2026, with an option to renew for one additional three year term. Supplemental information related to lease expense and valuation of the lease assets and lease liabilities are as follows: December 31, 2021 (in thousands) Operating lease expense $ 1,181 Variable lease expense 266 Total lease expense $ 1,447 Cash paid for amounts included in the measurement of operating lease liabilities $ 1,225 Leased assets obtained in exchange for new operating lease liabilities $ 2,896 Weighted average remaining lease term (in years) 3.98 Weighted average discount rate 5.75% Future minimum lease payments under non-cancelable operating leases as of December 31, 2021 was as follows: Year Ending December 31, (in thousands) 2022 $ 1,620 2023 1,544 2024 1,491 2025 990 2026 531 Thereafter 10 Total operating lease payments $ 6,186 Less: imputed interest (681) Total operating lease liabilities $ 5,505 As of December 31, 2021, the Company had no operating lease liabilities that had not commenced. As required, the following disclosure is provided for periods prior to adoption of Topic 842. Minimum lease commitments as of December 31, 2020 that had initial or remaining lease terms in excess of one year were as follows: Year Ending December 31, (in thousands) 2021 $ 1,081 2022 1,001 2023 908 2024 893 2025 381 Thereafter 24 $ 4,288 Rent expense charged to operations under operating leases totaled approximately $1.2 million for the year ended December 31, 2020. Purchase Commitments and Obligations The Company has certain purchase commitments related to its inventory management with certain manufacturing suppliers wherein the Company is required to purchase the amounts forecasted in a blanket purchase order. The contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude orders for goods and services entered into in the normal course of business that are not enforceable or legally binding. These outstanding commitments amounted to $1.2 million and $0.3 million as of December 31, 2021 and 2020, respectively. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date. |
Borrowings
Borrowings | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Borrowings | Borrowings Term Loan The following table summarizes the outstanding borrowings from the term loan as of the periods presented: December 31, 2021 December 31, 2020 (in thousands) Principal outstanding and final fee $ 35,700 $ 41,000 Less: Unamortized debt issuance costs (100) (661) Unaccreted value of final fee (627) (884) Outstanding debt, net of debt issuance costs and unaccreted value of final fee $ 34,973 $ 39,455 Classified as: Long-term borrowings $ 34,973 $ 39,455 In October 2017, the Company entered into a term loan with Biopharma Credit Investments IV Sub LP (“Pharmakon”) in for total loan proceeds of $40.0 million (the “Pharmakon Term Loan”). The Pharmakon Term Loan included an interest-only period for 35 months through September 2020 and then equal quarterly principal payments plus interest through December 2022. The Pharmakon Term Loan carried a fixed interest rate of 11.5% and allowed for early prepayment. The prepayment penalty fee was equal to the remaining interest due if prepaid within the first 30 months, a 2% penalty for months 31-48, and a 1% penalty for months 49-60. The Company paid in full and terminated the Pharmakon Term Loan in May 2020. The outstanding debt as of December 31, 2020 is related to a term loan pursuant to the Loan and Security Agreement dated May 29, 2020, entered into by the Company with Solar Capital Partners (“Solar”). Pursuant to the Loan and Security Agreement, Solar provided an aggregate principal amount of $40.0 million term loan (the “Solar Term Loan”). The total debt issuance costs of $0.8 million associated with the Solar Term Loan were recorded in the condensed consolidated balance sheet as a direct deduction from the carrying amount of the loan, and are amortized as a component of interest expense using straight-line method over the life of the term loan. In accordance with the Loan and Security Agreement with Solar, the Company paid in full and terminated the Pharmakon Term Loan, which was accounted for as debt extinguishment in accordance with the accounting standards. The Company recognized the unamortized debt issuance costs of $0.7 million and the prepayment penalty and lender fees of $0.8 million related to Pharmakon Term Loan as a loss on debt extinguishment. The costs and fees are reflected as interest expense in the consolidated statement of operations for the year ended December 31, 2020. The Solar Term Loan bore interest at a rate per annum equal to 9.40% plus London Interbank Offered Rate (“LIBOR”), payable monthly in arrears. LIBOR means the greater of (i) 0.33% or (ii) one-month LIBOR (or a comparable replacement rate to be determined by the collateral agent if the LIBOR is no longer available), which rate shall reset monthly. The Solar Term Loan included an interest-only period of 36 months through June 2023, and then repaid in equal monthly principal payments plus interest through June 1, 2025. Pursuant to the Loan and Security Agreement with Solar, the Company could voluntarily prepay the Solar Term Loan, in full or in part, but only in increments of $10.0 million, for a prepayment premium in an amount equal to 3.0% of the principal if prepaid in year one, 1.25% of the principal if prepaid in year two, and 0.50% of the principal if prepaid in year three or later. The Solar Term Loan was secured by substantially all of the Company’s assets. The Company was also obligated to pay a final fee equal to $1.0 million or 2.5% of the aggregate principal amount of the Solar Term Loan, which was fully earned by Solar on the effective date of the Loan and Security Agreement with Solar. With respect to the Solar Term Loan, this final fee shall be due and payable on the earliest of (i) the maturity date, (ii) the acceleration of the loan balance or (iii) its full prepayment, refinancing, substitution or replacement. The final fee was included within the long-term borrowings and was accreted to interest expense using straight-line method over the life of the term loan. The Company paid in full and terminated the Solar Term Loan in August 2021. The outstanding debt as of December 31, 2021 is related to a term loan pursuant to the Loan and Security Agreement dated August 12, 2021 (the “Effective Date”), entered into by the Company with Silicon Valley Bank (“SVB”). Pursuant the agreement, SVB provided an aggregate principal amount of $35.0 million to the Company (the “SVB Term Loan”). The Company used the proceeds of the SVB Term Loan to repay in full and terminate the Solar Term Loan, which was accounted for as debt extinguishment in accordance with the accounting standards. The Company recognized the unamortized debt issuance costs and unaccreted value of final fee of $1.3 million and the prepayment penalty and lender fees of $0.5 million related to Solar Term Loan as a loss on debt extinguishment. The costs and fees are reflected as interest expense in the condensed consolidated statement of operations for the three and nine months ended December 31, 2021. The total debt issuance costs of $0.1 million associated with the SVB Term Loan were recorded in the condensed consolidated balance sheet as a direct deduction from the carrying amount of the loan, and are amortized as a component of interest expense using straight-line method over the life of the term loan. The SVB Term Loan matures (the “Maturity Date”) on either (a) August 1, 2025 or (b) August 1, 2026 dependent on the Company’s achievement of a certain financial performance milestone as of December 31, 2022, as set forth in the Loan Agreement. Interest on the SVB Term Loan is payable monthly at an annual rate set at the greater of (a) 5.75% and (b) prime rate as published in the Wall Street Journal plus 2.5%. Commencing on September 1, 2023, the Company will be required to make monthly principal amortization payments. The Company may elect to prepay the SVB Term Loan prior to the Maturity Date subject to a prepayment fee equal to 1% if the prepayment occurs prior to the second anniversary of the Effective Date and —% if the prepayment occurs on or at any time after the second anniversary of the Effective Date. The SVB Term Loan is secured by substantially all the Company's assets other than the Company's intellectual property. The Company is also obligated to pay a final payment equal to $0.7 million or 2% of the aggregate principal amount of the SVB Term Loan, which is considered fully earned by SVB on the effective date of the Loan and Security Agreement with SVB. This final payment shall be due and payable on the earliest of (i) the maturity date, (ii) the full repayment of the loan, (iii) permitted prepayment and mandatory prepayment upon an acceleration as specified in the agreement or (iv) the termination of the agreement. The final payment is included within the long-term borrowings and is accreted to interest expense using straight-line method over the life of the term loan. The effective interest rate related to the SVB Term Loan and Solar Term Loan (excluding the write-down of unamortized debt issuance costs and prepayment penalty related to the Solar Term Loan) was 6.3% and 10.3%, respectively, for the year ended December 31, 2021. The effective interest rate related to the Pharmakon Term Loan and Solar Term Loan were 12.4% and 10.6%, respectively, for the year ended December 31, 2020. The table below summarizes the future principal and final fee payments under the SVB Term Loan as of December 31, 2021: Year ending December 31, (in thousands) 2022 $ — 2023 7,292 2024 17,500 2025 10,908 2026 — Total principal and final fee payments $ 35,700 The Loan Agreement includes affirmative and negative covenants applicable to the Company and certain of its foreign subsidiaries. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental compliance, deliver certain financial reports, and maintain insurance coverage. The negative covenants include, among others, restrictions regarding transferring collateral, pledging the Company's intellectual property to other parties, engaging in mergers or acquisitions, paying dividends or making other distributions, incurring indebtedness, transacting with affiliates, and entering into certain investments, in each case subject to certain exceptions. As of December 31, 2021, the Company was in compliance with all debt covenants. CARES Act On March 27, 2020, the U.S. federal government enacted the “Coronavirus Aid, Relief and Economic Security (CARES) Act,” which, among other things, established the Paycheck Protection Program (“PPP”), administered by the Small Business Administration (“SBA”), whereby certain small businesses were eligible for a loan to fund payroll expenses, rent, and related costs. The loan may be forgiven if the funds are used for payroll and other qualified expenses. The Company met the requirements to apply for the PPP loan given that the Company has less than 500 employees and the business was negatively impacted by COVID-19. The Company submitted its application and was approved for the SBA program and received the proceeds from the PPP loan amounting to $5.3 million on April 21, 2020, pursuant to a Promissory Note with Silicon Valley Bank (“SVB”). In light of the subsequent clarifications from the U.S. government on the eligibility criteria, the Company determined it was appropriate to repay the entire amount of the PPP loan. Accordingly, on April 29, 2020, the Company repaid in full the PPP loan and correspondingly terminated the Promissory Note. The CARES Act also allowed employers to def er the deposit and payment of an employer's share of social security taxes through December 31, 2020. A s of December 31, 2021, the Company recorded a liability of $0.5 million relat ed to the deferral of the social security taxes that is included in accrued liabilities in the consolidated balance sheet. As of December 31, 2020, t he Company recorded a total liability of $1.0 million relat |
Warrants
Warrants | 12 Months Ended |
Dec. 31, 2021 | |
Other Liabilities Disclosure [Abstract] | |
Warrants | Warrants The table below summarizes common stock warrants issued and outstanding at December 31, 2021 and 2020: Date Number of Price per Fair Value Issuance Expiration 3/1/2017 3/1/2027 [a] 1,388 $5.94 $ 5 [b] 7/22/2013 7/22/2023 [a] 32,983 $9.10 122 [b] 11/26/2014 11/26/2024 [a] 6,680 $16.47 49 [b] 10/20/2015 10/20/2025 [a] 41,650 $16.47 396 [c] 11/9/2015 11/9/2025 [a] 25,709 $16.47 244 [c] 12/22/2016 12/22/2026 [a] 9,712 $10.03 45 [c] 118,122 $ 861 [a] Common stock warrants will remain outstanding until the earlier of the expiration date or the date exercised by the holder. [b] Fair value at the date of issuance. [c] Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018. |
Common and Preferred Stock
Common and Preferred Stock | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Common and Preferred Stock | Common and Preferred Stock The Company's certificate of incorporate as amended and restated in October 2018, authorizes the Company to issue 100,000,000 shares of common stock and 5,000,000 shares of preferred stock, each having a par value of $0.0001. Common stock issued and outstanding as of December 31, 2021 and 2020 were 33,674,085 shares and 32,583,220 shares, respectively. As of December 31, 2021 and 2020, there was no preferred stock issued and outstanding. The holders of common stock are entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board of Directors. There have been no dividends declared to date. |
Stock-Based Compensation
Stock-Based Compensation | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation | Stock-Based Compensation 2008 Stock Option Plan and 2018 Equity Incentive Plan In April 2008, the Company adopted the 2008 Stock Option Plan (the “2008 SOP”), as amended, under which the Board of Directors may issue incentive and non-qualified stock options to employees, directors and consultants. In October 2018, the Company adopted the 2018 Equity Incentive Plan (the “2018 EIP”), which serves as the successor to the 2008 SOP, under which the Board of Directors may issue incentive and non-qualified stock options and RSUs to employees, directors and consultants. No new options have been granted under the 2008 SOP since August 2018. Outstanding options under the 2008 SOP continue to be subject to the terms and conditions of that plan. The number of shares of common stock reserved for issuance under the 2018 EIP will automatically increase on January 1 of each year, beginning January 1, 2019, and continuing through and including January 1, 2028, by 5% of the total number of shares of the Company's capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company's Board of Directors. As of December 31, 2021, a total of 3,520,102 shares of common stock are available for future grants under the 2018 EIP. On January 1, 2022, the total number of shares of common stock reserved for issuance under the 2018 EIP automatically increased by 1,683,704 shares. The Board of Directors has the authority to determine to whom options will be granted, the number of shares, the term and the exercise price. If an individual owns stock representing more than 10% of the outstanding shares, the price of each share shall be at least 110% of the fair market value, as determined by the Board of Directors. The exercise price of an incentive stock option and a non-qualified stock option shall not be less than 100% and 85%, respectively, of the fair market value on the date of grant. Options granted have a term of 10 years, except, options granted to individuals holding more than 10% of the outstanding shares have a term of five years. Options generally vest over a four-year period. Certain stock options are exercisable immediately, but are subject to a right of repurchase by the Company for any unvested shares. RSUs granted under the 2018 EIP generally vest over two Stock Options The following table summarizes stock option activity for the years ended December 31, 2021 and 2020: Options Outstanding Number of Shares Weighted-Average Exercise Price Weighted-Average Contractual Remaining Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2019 2,718,971 $8.02 Granted 26,236 $17.31 Exercised (323,701) $4.52 Canceled and forfeited (15,549) $17.07 Outstanding as of December 31, 2020 2,405,957 $8.54 Exercised (369,375) $6.94 Canceled and forfeited (27,069) $15.85 Outstanding as of December 31, 2021 2,009,513 $8.73 4.90 $ 27,089 Options vested and exercisable as of December 31, 2021 1,870,352 $7.81 4.73 $ 26,933 Options vested and expected to vest as of December 31, 2021 2,031,988 $8.61 5.12 $ 27,633 The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 amounted to $8.1 million and $5.6 million, respectively, representing the difference between the fair value of the Company's common stock at the date of exercise and the exercise price paid. The aggregate intrinsic values of options outstanding, options vested and exercisable, and options vested and expected to vest as of December 31, 2021 represents the difference between the exercise price and the closing price of the Company’s common stock on the last trading day of the year. Outstanding options and exercisable options information by range of exercise prices as of December 31, 2021 was as follows: Exercise Price Options Outstanding Options Vested and Exercisable Number of Shares Average Weighted- Number of Shares Weighted- $2.11 - $3.69 405,476 2.45 $3.36 405,476 $3.36 $3.70 - $4.41 517,272 3.98 $4.30 517,272 $4.30 $4.42 - $5.31 423,154 5.36 $4.67 421,812 $4.67 $5.32 - $20.51 254,817 6.44 $11.71 235,053 $11.29 $20.52 - $22.00 408,794 7.04 $22.00 290,739 $22.00 2,009,513 4.90 $8.73 1,870,352 $7.81 There were no stock options granted during the year ended December 31, 2021. The table below summarizes the weighted average grant date fair value per share and the assumptions used to estimate the grant date fair value using the Black-Scholes option-pricing model of the stock options granted during the periods presented: Year ended December 31, 2020 Weighted average grant date fair value per share $8.16 Expected term (years) 5.5 to 7 Expected volatility 46.7% to 47.2% Risk-free interest rate 1.6% to 1.6% Dividend yield —% As of December 31, 2021, there was $1.4 million of unrecognized compensation cost related to stock options granted. These costs are expected to be recognized over a period of approximately 1.0 years. Early Exercise of Unvested Stock Options Early exercises of stock options under the Company's 2008 SOP are subject to a right of repurchase by the Company of any unvested shares. The repurchase rights lapse over the original vesting period of the options. The Company accounts for the cash received in consideration for the early exercised options as a liability included in accrued liabilities, which is then reclassified to stockholders’ equity as the options vest. As of December 31, 2021, the Company had no shares subject to repurchase. As of December 31, 2020, the Company had a total 5,836 shares of common stock subject to repurchase under the 2008 SOP. Restricted Stock Units The following table summarizes restricted stock units activity for the years ended December 31, 2021 and 2020: Number of Weighted- Outstanding as of December 31, 2019 543,041 $19.72 Granted 1,016,432 $20.17 Vested (344,779) $19.87 Canceled and forfeited (49,399) $19.73 Outstanding as of December 31, 2020 1,165,295 $20.07 Granted 1,187,143 $28.46 Vested (574,195) $21.76 Canceled and forfeited (211,721) $24.76 Outstanding as of December 31, 2021 1,566,522 $25.17 As of December 31, 2021, there was a total unrecognized compensation cost of $32.6 million. These costs are expected to be recognized over a period of approximately 2.7 years. Employee Stock Purchase Plan The Company’s 2018 Employee Stock Purchase Plan (the “ESPP”) allows eligible employees to purchase shares of the Company's common stock through payroll deductions at the price equal to 85% of the lesser of the fair market value of the stock as of the first date or the ending date of each six month offering period. The offering period generally commences in May and November. On March 26, 2020, the Company's Compensation Committee approved the amendment of the terms of future offerings under the ESPP which, among other things, increased the maximum number of shares that may be purchased on any single purchase date, provided for automatic enrollment in a new offering, and provided that the offering which commenced in May 2020 be twelve months in duration and consist of two purchase periods. As of December 31, 2021, a total of 884,155 shares of common stock are available for future grants under the 2018 EIP. On January 1, 2022, the total number of shares of common stock reserved for issuance under the ESPP Plan increased by 336,741 shares. The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model, which is being amortized over the requisite service period. The Company issued 147,295 shares and 137,377 shares under the ESPP during the years ended December 31, 2021 and 2020, respectively, representing approximately $2.3 million and $1.9 million in employee contributions. As of December 31, 2021 and 2020, total accumulated ESPP related employee payroll deductions amounted to $0.3 million and $0.4 million, respectively, which were included within accrued compensation and related expenses in the consolidated balance sheets. For the years ended December 31, 2021 and 2020, the Company recognized $0.8 million and $1.2 million, respectively, of stock-based compensation expense related to ESPP. As of December 31, 2021, the unrecognized compensation cost for the ESPP wa s $0.3 million. The Company estimated the fair value of ESPP purchase rights during the offering period using a Black-Scholes option pricing model with the following assumptions: Year Ended December 31, 2021 2020 Expected term (years) 0.5 0.5 to 1.0 Expected volatility 48.8% to 49.5% 38.3% to 79.4% Risk-free interest rate 0.04% to 0.07% 0.10% to 1.60% Dividend yield —% —% Stock-Based Compensation The following table sets forth stock-based compensation expense recognized for the periods presented: Year Ended December 31, 2021 2020 (in thousands) Cost of goods sold $ 530 $ 331 Sales and marketing 8,448 5,527 Research and development 1,710 1,139 General and administrative 6,178 4,930 $ 16,866 $ 11,927 |
Employee Benefit Plan
Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2021 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plan | Employee Benefit PlanThe Company sponsors a 401(k) plan covering all employees. Contributions made by the Company are discretionary and are determined annually by the Board of Directors. Effective January 1, 2019, the Company made a discretionary matching contribution equal to dollar for dollar employee contribution, up to 3% eligible compensation of the employee, with a maximum annual contribution from the Company of one thousand dollars per employee. Further, in order for an employee to receive the matching contribution, the employee must be at least 21 years old, work at least 1,000 hours per year, and must be employed by the Company at the beginning through the end of the year. For the years ended December 31, 2021 and 2020, the Company made $0.2 million contributions to the 401(k) plan. |
Net Loss Per Share of Common St
Net Loss Per Share of Common Stock | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share of Common Stock | Net Loss Per Share of Common Stock The following table summarizes the computation of basic and diluted net loss per share: Year Ended December 31, 2021 2020 (in thousands, except share and per share data) Net loss $ (56,572) $ (43,697) Weighted-average shares used to compute basic and diluted net loss per share 33,145,930 29,059,171 Net loss per share, basic and diluted $ (1.71) $ (1.50) Because the Company has reported a net loss in all periods presented, outstanding stock options, restricted stock units, shares subject to repurchase, ESPP purchase rights and common stock warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for the periods presented. The following anti-dilutive common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented: Year Ended December 31, 2021 2020 Stock options 2,009,513 2,405,957 Restricted stock units 1,566,522 1,165,295 Shares subject to repurchase — 5,836 ESPP purchase rights 61,264 83,040 Common stock warrants 118,122 118,122 3,755,421 3,778,250 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The components of the Company’s loss before income taxes are as follows: Year Ended December 31, 2021 2020 (in thousands) Domestic $ (57,035) $ (41,708) Foreign 463 (1,989) Loss before income taxes $ (56,572) $ (43,697) There was no provision for income taxes recorded for the years ended December 31, 2021 and 2020. The Company continues to maintain a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets. The Company periodically evaluates the realizability of its net deferred tax assets based on the expected realization and is dependent on the Company's ability to generate sufficient future taxable income during periods prior to the expiration of tax attributes to fully utilize these assets. The components of deferred income taxes are as follows: Year Ended December 31, 2021 2020 (in thousands) Federal $ 12,994 $ 9,855 State 1,878 2,711 Foreign 461 583 Total deferred income taxes 15,333 13,149 Change in deferred tax valuation allowance (15,333) (13,149) Net deferred income tax $ — $ — Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: Year Ended December 31, 2021 2020 Tax at statutory federal rate (21.0) % (21.0) % State tax, net of federal benefit (3.3) % (6.2) % Tax credits (0.8) % (0.7) % Change in deferred tax valuation allowance 27.1 % 30.1 % Stock compensation (1.7) % (1.2) % Foreign rate differences 0.1 % (1.3) % Other (0.4) % 0.3 % Total income tax expense — % — % The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below: Year Ended December 31, 2021 2020 (in thousands) Net operating loss carryforwards $ 66,015 $ 52,331 Research and development credits 3,837 3,160 Accruals and reserves 1,994 2,669 Interest limitation 3,995 2,781 Stock compensation 2,728 2,395 Depreciation and amortization 152 117 Operating lease liabilities 1,376 — Total deferred tax assets 80,097 63,453 Operating lease right-of-use assets (1,311) — Total deferred tax liabilities (1,311) — Less: Valuation allowance (78,786) (63,453) Total deferred tax asset, net of valuation allowance $ — $ — The following table summarizes changes in the valuation allowance for the years ended December 31, 2021 and 2020: Year Ended December 31, 2021 2020 (in thousands) Beginning balance $ 63,453 $ 50,304 Net changes during the period 15,333 13,149 Ending balance $ 78,786 $ 63,453 As of December 31, 2021, the Company had net operating loss (“NOL”) carryforwards of approximately $255.5 million and $203.2 million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. If not utilized, the Company’s federal NOL carryforward begins to expire in 2029, and the state NOL carryforward began to expire in 2021. As of December 31, 2021, the Company had credit carryforwards of approximately $3.2 million and $2.9 million available to reduce future taxable income, if any, for both federal and state income tax purposes, respectively. The federal credits begin to expire in 2029, and the state credits have no expiration date. The Company updated its Section 382 ownership change analysis through December 31, 2020 and determined that the last ownership change was in February 202 0 due to the follow-offering. The analysis concluded that no additional NOL carryforwards will expire due to the Section 382 limitation from the ownership change for both federal and state tax purposes. The Company maintains the reduction of $1.4 million of its NOL carryforwards from the previous ownership change. The equity shift between December 31, 2020 to December 31, 2021 was not material, considering the changes in the outstanding number of shares during the period. The Company reasonably believes no additional ownership change occurred in the current year. The Company will continually assess the need to update its Section 382 ownership change analysis, as the Company may experience ownership changes in the future that could materially limit its ability to use its NOL carryforwards. The CARES Act includes provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company deferred the payment of an employer's share of social security taxes through December 31, 2021 of $0.5 million. On June 29, 2020, Governor Gavin Newsom signed California Assembly Bill 85 (AB 85) into law. The legislation suspends the California net operating loss deductions for 2020, 2021, and 2022 for certain taxpayers and imposes a limitation of certain California Tax Credits for 2020, 2021, and 2022. The legislation disallows the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted gross income is greater than $1.0 million. The carryover periods for net operating loss deductions disallowed by this provision will be extended. Additionally, any business credit will only offset a maximum of $5.0 million of California tax. The Company will continue to monitor the possible California net operating loss and credit limitations in future periods. On February 9, 2022, Governor Gavin Newsom signed California Senate Bill 113 (SB 113) into law. The legislation contains important California tax law changes, including reinstatement of business tax credits and net NOL deductions limited by AB 85 mentioned above. The new tax law should be accounted for under ASC 740 in the period of enactment (2022) but is not expected to have a material impact on the Company’s tax provision due to its taxable loss position. The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. The changes in the Company’s uncertain income tax positions for the years ended December 31, 2021 and 2020 consisted of the following: Year ended December 31, 2021 2020 (in thousands) Balance at beginning of the year $ 1,513 $ 1,287 Increases related to tax positions taken prior to current year 817 — Increases related to current year's tax positions 325 226 Balance at end of the year $ 2,655 $ 1,513 The Company has elected to recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The Company has no accrued interest related to unrecognized tax benefits as of December 31, 2021 and 2020. None of the Company’s unrecognized tax benefits that, if recognized, would affect its effective tax rates for the years ended December 31, 2021 and 2020. The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company currently has no federal, state or foreign tax examinations in progress nor has it had any federal or state examinations since inception. As a result of the Company’s net operating loss carry forwards, all of its tax years are subject to federal and state tax examinations. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions On February 24, 2020, the Company entered into a joint development agreement (the “Development Agreement”) with SeaSpine Orthopedics Corporation (“SeaSpine”) to develop a next generation device for sacropelvic fixation. Mr. Keith Valentine, who serves as the President, Chief Executive Officer and a member of the board of directors of SeaSpine, also serves as a member of the Company's Board of Directors since August 2015. On April 27, 2021, Addendum No.1 to the Development Agreement was entered into by and between the Company and SeaSpine to extend certain obligations as described under the Development Agreement to a consultant of the Company. Pursuant to the development plan, SeaSpine shall use reasonable efforts to assist in the development of the potential product offering, including licensing certain existing intellectual property to be incorporated into such product. Under the terms of the Development Agreement, the Company agreed to make monthly payments to SeaSpine to reimburse for full time resources employed by SeaSpine responsible to conduct the development activities. For the years ended December 31, 2021 and 2020, the Company expensed $29,000 and $118,000, respectively, of the reimbursement charges from SeaSpine. The reimbursement charges were recorded within research and development expense in the consolidated statement of operations. There was no outstanding liabilities to SeaSpine as of December 31, 2021. Certain intellectual property developed pursuant to the project plan will be owned by the Company, certain intellectual property developed pursuant to the project plan will be owned by SeaSpine, and other intellectual property developed pursuant to the project plan will be jointly owned by SeaSpine and the Company. The Company also agreed to provide SeaSpine a royalty-free, worldwide, perpetual, non-exclusive license of certain of the Company's intellectual property incorporated into the product to be developed. The Company also agreed to pay SeaSpine a product royalty, in an amount specified in the Development Agreement, for each resulting product sold for a period of 10 years beginning on the initial market launch. The term of the Development Agreement shall continue until the expiration of all royalty terms, unless earlier terminated by either party, as provided for by the Development Agreement. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). |
Principles of Consolidation | The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period . Significant accounting estimates and management judgments reflected in the consolidated financial statements primarily includes the fair value of stock options. |
Segments | Segments The Company's chief operating decision makers are the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”). The CEO and the CFO review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. |
Foreign Currency | Foreign Currency The Company’s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses from foreign currency translation are recorded as a component of accumulated other comprehensive income (loss). Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company’s cash and marketable securities are deposited with financial institutions in the U.S. and in Europe. The majority of the Company’s cash and marketable securities are deposited with a single financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy as defined below. The carrying value of the Company’s long-term debt also approximates fair value based on management’s estimation that a current interest rate would not differ materially from the stated rate. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents. |
Marketable Securities | Marketable Securities The Company's marketable securities primarily consist of investments in money market funds, U.S. treasury securities, corporate bonds and commercial paper. All of the Company's marketable securities are available-for-sale and are classified based on their maturities. Marketable securities with remaining maturities at the date of purchase of three months or less are classified as cash equivalents. Short term investments are securities that original or remaining maturity is greater than three months and not more than twelve months. Long-term investments are securities that original or remaining maturity is more than twelve months. All marketable securities are recorded at their estimated fair value. When the fair value of a security is below its amortized cost, the amortized cost will be reduced to its fair value if it is more likely than not that the Company will be required to sell the potentially impaired security before recovery of its amortized cost basis, or the Company has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost over the fair value of the security. An allowance for credit losses for the excess of amortized cost over the expected cash flows is recorded in other income, net in the consolidated statements of operations. Impairment losses that are not credit-related are included in accumulated other comprehensive income (loss) in stockholders’ equity. |
Accounts Receivable and Allowance for Credit Losses | Accounts Receivable and Allowance for Credit LossesTrade accounts receivable are recorded at the invoiced amount, net of allowances for credit losses for any potential uncollectible amounts. The allowance for credit losses is based on our assessment of the collectability of accounts. Management regularly reviews the adequacy of the allowance for credit losses on a collective basis by considering the age of each outstanding invoice, each customer’s expected ability to pay and collection history, current market conditions, and reasonable and supportable forecasts of future economic conditions to determine whether the allowance is appropriate. Accounts receivable are written-off and charged against an allowance for credit losses when the Company has exhausted collection efforts without success. For the years ended December 31, 2021 and 2020, the allowance for credit losses activity was not significant. |
Inventory | InventoryInventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the purchase costs on a first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. |
Property and Equipment | Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows: Computer and office equipment 3 – 5 years Machinery and equipment 3 – 5 years Furniture and fixtures 7 years Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred. |
Impairment of Long-Lived Assets | Impairment of Long-Lived AssetsThe Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets (or asset group) may not be fully recoverable. Whenever events or changes in circumstances suggest that the carrying amount of long-lived assets may not be recoverable, the Company estimates the future cash flows expected to be generated by the assets (or asset group) from its use or eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Significant management judgment is required in the grouping of long-lived assets and forecasts of future operating results that are used in the discounted cash flow method of valuation. |
Leases | Leases The Company determines if an arrangement is a lease at inception. The classification of leases is evaluated at commencement and, as necessary, at modification. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheets. The Company does not have any material finance leases in any of the periods presented. Under Accounting Standards Update ("ASU") 2016-02, Leases Topic 842 ("Topic 842"), operating lease expense is recognized on a straight-line basis over the term of the lease. Variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The lease term represents the non-cancelable period of the lease. For certain leases, the Company has an option to extend the lease term. These renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options. |
Revenue Recognition | Revenue Recognition The Company’s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the U.S. and Europe. The Company adopted the revenue standard in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) effective for the fiscal year ended December 31, 2019. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services. Under the revenue recognition standard, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. As it relates to product sales where the Company's sales representative delivers the product at the point of implantation at the hospital or medical facilities, the Company continues to recognize the revenue upon completion of the procedure and authorization by the customer, net of rebates and price discounts. This represents the majority of the Company's consolidated revenue. The Company also generates a small portion of revenue from the sale of products through distributors and to certain hospital or medical facilities where the products are ordered in advance of a procedure. The performance obligation is the delivery of the products and therefore, revenue is recognized upon shipment to the customers, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there had been no significant price discounts. Sales prices are specified in either the customer contract or agreed price list, which is executed prior to the transfer of control to the customer. For certain hospitals and medical facilities, the Company has agreements in place consists of either a master services agreement or an agreed price list, which defines the terms and conditions of the arrangement, including the pricing information, payment terms and pertinent aspects of the relationship between the parties. The Company also has agreements in place with its distributors, which include standard terms that do not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor’s payment obligation. The Company's standard payment terms are generally net 30 to 90 days. Shipping and Handling Costs Shipping and handling costs are treated as fulfillment costs, which are expensed as incurred and are included in cost of goods sold. Costs to Obtain Customer Contracts |
Warranty Program | Warranty The Company has a warranty program that provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a one-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the one-year period following an original procedure where an implant is not required. The warranty is not priced or sold separately and is intended to safeguard the customer against defects and it does not provide incremental service to the customer. As such, it is considered an assurance type warranty and is not accounted as a service type warranty, which could represent a separate performance obligation. The Company accounts for these one-time credits as sales reserves and is included in accrued liabilities and other in the consolidated balance sheets. |
Research and Development | Research and Development Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company’s product which primarily include: (1) employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; (2) external research and development expenses; and (3) other expenses, which include direct and allocated expenses for facilities and other costs. |
Advertising Expenditures | Advertising ExpendituresThe cost of advertising is expensed as incurred and is included under sales and marketing expense in the consolidated statements of operations. |
Loss Contingency | Loss ContingencyThe Company is subject to various potential loss contingencies arising in the ordinary course of business. From time to time, the Company may be involved in certain proceedings, legal actions and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within the Company's control and may not be known for prolonged periods of time. In some actions, the claimants may seek damages, as well as other relief, including injunctions which may prohibit the Company to engage in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. The Company records a liability in the consolidated financial statements when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. |
Stock-Based Compensation | Stock-Based Compensation The Company applies the fair value recognition provisions of stock-based compensation. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised. The Company estimates the grant date fair value of stock options using the Black-Scholes option valuation model. The model requires management to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividends. A number of these assumptions are subjective, and their determination generally require judgment. • Expected Term - The expected term represents the period that the share-based awards are expected to be outstanding. The Company uses the simplified method to determine the expected term as permitted by the guidance since the Company has no sufficient historical exercise patterns to estimate the expected life. The simplified method is calculated as the average of the time to vesting and the contractual life of the options. • Expected Volatility - The expected volatility is measured using the historical daily changes in the market price of the Company's common stock over a period consistent with the expected term. • Risk-Free Interest Rate - The risk-free interest rate is based on the U.S. Treasury zero coupon issued in effect at the time of grant for periods corresponding with the expected term of the option. • Dividend Yield - The Company has not paid any dividends and has no current plans to pay dividends on its common stock. As such, the Company uses expected dividend yield of zero. The fair value of the restricted stock unit (“RSU”) grant is based on the market price of the Company’s common stock on the date of grant. Prior to the Company's initial public offering (“IPO”), the fair value of the shares of the Company's common stock has historically been determined by its Board of Directors since there were no public market information available for the Company's common stock. The estimated fair value of the Company's common stock was determined at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation . Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the Nasdaq Global Market on the date of grant. Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned. |
Income Taxes | Income Taxes The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. |
Net Loss per Share of Common Stock | Net Loss per Share of Common Stock The Company calculates basic and diluted net loss per common share attributable to shareholders i n conformity with the two-class method required for companies with participating securities. The Company considers all ea rly exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the early exercised stock options as the holders do not have a contractual obligation to share in losses. Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, restricted stock units and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss represents all changes in the stockholders’ equity except those resulting from distributions to stockholders. The Company’s unrealized foreign currency translation income (losses) and unrealized gains (losses) on marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss. |
Warrants | WarrantsThe Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i) indexed to the entity’s own stock and (ii) classified in the stockholders’ equity section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made. |
Recent Accounting Pronouncements | Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which requires that lessee's recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet. In July 2018, the FASB issued ASU 2018-10 and ASU 2018-11, which provides clarification on the narrow aspects of the guidance and provide an additional transition method to adopt the new leases standard. In March 2019, the FASB issued ASU 2019-01, which provides clarification on implementation issues associated with adopting ASU 2016-02. The new leases standard must be adopted using a modified retrospective transition method and allows for the application of the new guidance at the beginning of the earliest comparative period presented or at the adoption date. In November 2019, the FASB issued ASU 2019-10, which revised the mandatory effective dates of the new leases standard. Further, due to the impact of the COVID-19, in June 2020, the FASB issued ASU 2020-05 to further defer the effective date for one year for entities in the “all other” categories. In the fourth quarter of 2021, the Company adopted Topic 842 for leases, using the modified retrospective method, applying Topic 842 to all leases existing at the date of initial application. The Company elected to use the effective date of January 1, 2021 as the date of initial application. Under the modified retrospective method, balances and disclosures prior to January 1, 2021 have not been restated. The Company elected certain practical expedients, which among other things, allowed the Company to carry forward prior conclusions about lease identification and classification. The adoption of ASC 842 had a material impact on the consolidated balance sheet as the standard requires the Company to measure and recognize a right of use asset and lease liability. The Company recognized $3.8 million of operating lease liabilities and approximately $3.5 million of operating lease right-of-use assets on the consolidated balance sheet as of January 1, 2021. The difference between the operating lease right-of-use assets and operating lease liabilities represented the existing deferred rent liability balance as of the adoption date of $0.3 million. The adoption of the standard did not have a material impact on the consolidated statement of operations and comprehensive loss and there was no impact to cash from or used in operating, financing or investing activities on the consolidated statement of cash flows. The adoption of ASC Topic 842 had no income tax impact to the financial statements. The Company accounted for the basis differences arising from ASC Topic 842 adoption in deferred taxes which was offset by a valuation allowance. In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). FASB issued ASU 2019-05 in May 2019, ASU 2019-08 and ASU 2019-11 in November 2019 for codification improvements of Topic 326. In November 2019, the FASB issued ASU 2019-10, which defers the effective date of ASU 2016-13 for public companies that are eligible to be smaller reporting companies and all other companies, to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. In February 2020, the FASB issued ASU 2020-02, which provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses. ASU 2016-13 revises the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses for certain financial instruments and financial assets. For trade receivables, the Company is required to estimate lifetime expected credit losses. For available-for-sale debt securities, the Company will recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2021 on a modified retrospective basis. The Company adopted this standard effective for the year ended December 31, 2021, and the adoption did not have a material impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating incomes taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 is effective in 2021 and interim periods within that year and permits for an early adoption. The Company adopted ASU 2019-12 effective January 1, 2021. The adoption of the guidance did not have a material impact on its financials statements and related disclosures. Recently Issued Accounting Standards Not Yet Adopted In May 2021, the FASB issued ASU 2021-04 “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” ("ASU 2021-04") which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: i) for a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged; ii) for all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company is currently evaluating the impact of this update on its consolidated financial statements. While the Company does not expect the adoption of ASU 2021-04 to materially impact the Company's consolidated financial statements and related disclosures because it does not currently anticipate modifications to its outstanding equity-classified written call options, the impact on the Company's consolidated financial statements and disclosures will depend on the facts and circumstances of any specific future transactions. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Schedule of Revenue by Geography | Following table summarizes the Company's revenue by geography: Year Ended December 31, 2021 2020 (in thousands) United States $ 82,739 $ 68,118 International 7,413 5,269 $ 90,152 $ 73,387 |
Schedule of Allowance for Credit Losses Movement | The movement in the allowance for credit losses was as follows: Year ended December 31, 2021 2020 (in thousands) Balance at beginning of year $ 263 $ 238 Provision 14 234 Write-offs (13) (209) Balance at end of year $ 264 $ 263 |
Schedule of Property and Equipment | All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows: Computer and office equipment 3 – 5 years Machinery and equipment 3 – 5 years Furniture and fixtures 7 years Property and Equipment, net : December 31, 2021 December 31, 2020 (in thousands) Machinery and equipment $ 10,573 $ 6,342 Construction in progress 3,657 1,692 Computer and office equipment 916 714 Leasehold improvements 503 503 Furniture and fixtures 309 233 15,958 9,484 Less: Accumulated depreciation and amortization (6,966) (4,957) $ 8,992 $ 4,527 |
Marketable Securities (Tables)
Marketable Securities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of Marketable Securities | The table below summarizes the marketable securities: December 31, 2021 Amortized Cost Unrealized Gains Unrealized Losses Aggregate Fair Value (in thousands) Money market funds $ 57,829 $ — $ — $ 57,829 Cash equivalents 57,829 — — 57,829 U.S. treasury securities 28,064 — (16) 28,048 Corporate bonds 31,558 4 (23) 31,539 Commercial paper 23,973 — — 23,973 Short-term investments 83,595 4 (39) 83,560 Total marketable securities $ 141,424 $ 4 $ (39) $ 141,389 December 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Aggregate Fair Value (in thousands) Money market funds $ 45,948 $ — $ — $ 45,948 Commercial paper 1,400 — — 1,400 Cash equivalents 47,348 — — 47,348 U.S. treasury securities 74,779 4 (7) 74,776 Corporate bonds 8,940 4 (6) 8,938 Commercial paper 59,137 — — 59,137 Short-term investments 142,856 8 (13) 142,851 Total marketable securities $ 190,204 $ 8 $ (13) $ 190,199 |
Fair Value Measurement (Tables)
Fair Value Measurement (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis | The table below summarizes the fair value of the Company’s marketable securities measured at fair value on a recurring basis based on the three-tier fair value hierarchy: December 31, 2021 Level 1 Level 2 Level 3 Total (in thousands) Marketable securities Money market funds $ 57,829 $ — $ — $ 57,829 U.S. treasury securities 28,048 — — 28,048 Corporate bonds — 31,539 — 31,539 Commercial paper — 23,973 — 23,973 Total marketable securities $ 85,877 $ 55,512 $ — $ 141,389 December 31, 2020 Level 1 Level 2 Level 3 Total (in thousands) Marketable securities Money market funds $ 45,948 $ — $ — $ 45,948 U.S. treasury securities 74,776 — — 74,776 Corporate bonds — 8,938 — 8,938 Commercial paper — 60,537 — 60,537 Total marketable securities $ 120,724 $ 69,475 $ — $ 190,199 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Property and Equipment, Net | All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows: Computer and office equipment 3 – 5 years Machinery and equipment 3 – 5 years Furniture and fixtures 7 years Property and Equipment, net : December 31, 2021 December 31, 2020 (in thousands) Machinery and equipment $ 10,573 $ 6,342 Construction in progress 3,657 1,692 Computer and office equipment 916 714 Leasehold improvements 503 503 Furniture and fixtures 309 233 15,958 9,484 Less: Accumulated depreciation and amortization (6,966) (4,957) $ 8,992 $ 4,527 |
Schedule of Accrued Liabilities and Other | Accrued Liabilities and Other : December 31, 2021 December 31, 2020 (in thousands) Accrued compensation and related expenses $ 10,055 $ 9,175 Accrued professional services 995 511 Others 1,303 513 $ 12,353 $ 10,199 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Lease Costs | Supplemental information related to lease expense and valuation of the lease assets and lease liabilities are as follows: December 31, 2021 (in thousands) Operating lease expense $ 1,181 Variable lease expense 266 Total lease expense $ 1,447 Cash paid for amounts included in the measurement of operating lease liabilities $ 1,225 Leased assets obtained in exchange for new operating lease liabilities $ 2,896 Weighted average remaining lease term (in years) 3.98 Weighted average discount rate 5.75% |
Schedule of Future Minimum Lease Payments, Post ASC 842 Adoption | Future minimum lease payments under non-cancelable operating leases as of December 31, 2021 was as follows: Year Ending December 31, (in thousands) 2022 $ 1,620 2023 1,544 2024 1,491 2025 990 2026 531 Thereafter 10 Total operating lease payments $ 6,186 Less: imputed interest (681) Total operating lease liabilities $ 5,505 |
Schedule of Future Minimum Lease Payments, Pre ASC 842 Adoption | As required, the following disclosure is provided for periods prior to adoption of Topic 842. Minimum lease commitments as of December 31, 2020 that had initial or remaining lease terms in excess of one year were as follows: Year Ending December 31, (in thousands) 2021 $ 1,081 2022 1,001 2023 908 2024 893 2025 381 Thereafter 24 $ 4,288 |
Borrowings (Tables)
Borrowings (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Outstanding Borrowings | The following table summarizes the outstanding borrowings from the term loan as of the periods presented: December 31, 2021 December 31, 2020 (in thousands) Principal outstanding and final fee $ 35,700 $ 41,000 Less: Unamortized debt issuance costs (100) (661) Unaccreted value of final fee (627) (884) Outstanding debt, net of debt issuance costs and unaccreted value of final fee $ 34,973 $ 39,455 Classified as: Long-term borrowings $ 34,973 $ 39,455 |
Schedule of Annual Future Minimum Principal Payments Under Loan Agreements | Year ending December 31, (in thousands) 2022 $ — 2023 7,292 2024 17,500 2025 10,908 2026 — Total principal and final fee payments $ 35,700 |
Warrants (Tables)
Warrants (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Other Liabilities Disclosure [Abstract] | |
Schedule of Warrants Issued and Outstanding | The table below summarizes common stock warrants issued and outstanding at December 31, 2021 and 2020: Date Number of Price per Fair Value Issuance Expiration 3/1/2017 3/1/2027 [a] 1,388 $5.94 $ 5 [b] 7/22/2013 7/22/2023 [a] 32,983 $9.10 122 [b] 11/26/2014 11/26/2024 [a] 6,680 $16.47 49 [b] 10/20/2015 10/20/2025 [a] 41,650 $16.47 396 [c] 11/9/2015 11/9/2025 [a] 25,709 $16.47 244 [c] 12/22/2016 12/22/2026 [a] 9,712 $10.03 45 [c] 118,122 $ 861 [a] Common stock warrants will remain outstanding until the earlier of the expiration date or the date exercised by the holder. [b] Fair value at the date of issuance. [c] Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018. |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Stock Option Activity | The following table summarizes stock option activity for the years ended December 31, 2021 and 2020: Options Outstanding Number of Shares Weighted-Average Exercise Price Weighted-Average Contractual Remaining Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2019 2,718,971 $8.02 Granted 26,236 $17.31 Exercised (323,701) $4.52 Canceled and forfeited (15,549) $17.07 Outstanding as of December 31, 2020 2,405,957 $8.54 Exercised (369,375) $6.94 Canceled and forfeited (27,069) $15.85 Outstanding as of December 31, 2021 2,009,513 $8.73 4.90 $ 27,089 Options vested and exercisable as of December 31, 2021 1,870,352 $7.81 4.73 $ 26,933 Options vested and expected to vest as of December 31, 2021 2,031,988 $8.61 5.12 $ 27,633 |
Schedule of Options by Range of Exercise Price | Outstanding options and exercisable options information by range of exercise prices as of December 31, 2021 was as follows: Exercise Price Options Outstanding Options Vested and Exercisable Number of Shares Average Weighted- Number of Shares Weighted- $2.11 - $3.69 405,476 2.45 $3.36 405,476 $3.36 $3.70 - $4.41 517,272 3.98 $4.30 517,272 $4.30 $4.42 - $5.31 423,154 5.36 $4.67 421,812 $4.67 $5.32 - $20.51 254,817 6.44 $11.71 235,053 $11.29 $20.52 - $22.00 408,794 7.04 $22.00 290,739 $22.00 2,009,513 4.90 $8.73 1,870,352 $7.81 |
Schedule of Valuation Assumptions Related to Stock Option Awards | Year ended December 31, 2020 Weighted average grant date fair value per share $8.16 Expected term (years) 5.5 to 7 Expected volatility 46.7% to 47.2% Risk-free interest rate 1.6% to 1.6% Dividend yield —% |
Schedule of Restricted Stock Unit Activity | The following table summarizes restricted stock units activity for the years ended December 31, 2021 and 2020: Number of Weighted- Outstanding as of December 31, 2019 543,041 $19.72 Granted 1,016,432 $20.17 Vested (344,779) $19.87 Canceled and forfeited (49,399) $19.73 Outstanding as of December 31, 2020 1,165,295 $20.07 Granted 1,187,143 $28.46 Vested (574,195) $21.76 Canceled and forfeited (211,721) $24.76 Outstanding as of December 31, 2021 1,566,522 $25.17 |
Schedule of Valuation Assumptions Related to ESPP Purchase Rights | The Company estimated the fair value of ESPP purchase rights during the offering period using a Black-Scholes option pricing model with the following assumptions: Year Ended December 31, 2021 2020 Expected term (years) 0.5 0.5 to 1.0 Expected volatility 48.8% to 49.5% 38.3% to 79.4% Risk-free interest rate 0.04% to 0.07% 0.10% to 1.60% Dividend yield —% —% |
Schedule of Stock-Based Compensation Expense | Stock-Based Compensation The following table sets forth stock-based compensation expense recognized for the periods presented: Year Ended December 31, 2021 2020 (in thousands) Cost of goods sold $ 530 $ 331 Sales and marketing 8,448 5,527 Research and development 1,710 1,139 General and administrative 6,178 4,930 $ 16,866 $ 11,927 |
Net Loss Per Share of Common _2
Net Loss Per Share of Common Stock (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and Diluted Net Loss per Share | The following table summarizes the computation of basic and diluted net loss per share: Year Ended December 31, 2021 2020 (in thousands, except share and per share data) Net loss $ (56,572) $ (43,697) Weighted-average shares used to compute basic and diluted net loss per share 33,145,930 29,059,171 Net loss per share, basic and diluted $ (1.71) $ (1.50) |
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share | Year Ended December 31, 2021 2020 Stock options 2,009,513 2,405,957 Restricted stock units 1,566,522 1,165,295 Shares subject to repurchase — 5,836 ESPP purchase rights 61,264 83,040 Common stock warrants 118,122 118,122 3,755,421 3,778,250 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Components of Loss Before Income Taxes | The components of the Company’s loss before income taxes are as follows: Year Ended December 31, 2021 2020 (in thousands) Domestic $ (57,035) $ (41,708) Foreign 463 (1,989) Loss before income taxes $ (56,572) $ (43,697) |
Schedule of Components of Income Tax Expense | The components of deferred income taxes are as follows: Year Ended December 31, 2021 2020 (in thousands) Federal $ 12,994 $ 9,855 State 1,878 2,711 Foreign 461 583 Total deferred income taxes 15,333 13,149 Change in deferred tax valuation allowance (15,333) (13,149) Net deferred income tax $ — $ — |
Schedule of Effective Income Tax Rate Reconciliation | Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: Year Ended December 31, 2021 2020 Tax at statutory federal rate (21.0) % (21.0) % State tax, net of federal benefit (3.3) % (6.2) % Tax credits (0.8) % (0.7) % Change in deferred tax valuation allowance 27.1 % 30.1 % Stock compensation (1.7) % (1.2) % Foreign rate differences 0.1 % (1.3) % Other (0.4) % 0.3 % Total income tax expense — % — % |
Schedule of Deferred Tax Assets | The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below: Year Ended December 31, 2021 2020 (in thousands) Net operating loss carryforwards $ 66,015 $ 52,331 Research and development credits 3,837 3,160 Accruals and reserves 1,994 2,669 Interest limitation 3,995 2,781 Stock compensation 2,728 2,395 Depreciation and amortization 152 117 Operating lease liabilities 1,376 — Total deferred tax assets 80,097 63,453 Operating lease right-of-use assets (1,311) — Total deferred tax liabilities (1,311) — Less: Valuation allowance (78,786) (63,453) Total deferred tax asset, net of valuation allowance $ — $ — |
Summary of Changes in Valuation Allowance | The following table summarizes changes in the valuation allowance for the years ended December 31, 2021 and 2020: Year Ended December 31, 2021 2020 (in thousands) Beginning balance $ 63,453 $ 50,304 Net changes during the period 15,333 13,149 Ending balance $ 78,786 $ 63,453 |
Schedule of Uncertain Income Tax Positions | The changes in the Company’s uncertain income tax positions for the years ended December 31, 2021 and 2020 consisted of the following: Year ended December 31, 2021 2020 (in thousands) Balance at beginning of the year $ 1,513 $ 1,287 Increases related to tax positions taken prior to current year 817 — Increases related to current year's tax positions 325 226 Balance at end of the year $ 2,655 $ 1,513 |
The Company and Nature of Bus_2
The Company and Nature of Business (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended |
Oct. 31, 2020 | Mar. 31, 2020 | |
First follow-on public offering | ||
Subsidiary, Sale of Stock [Line Items] | ||
Net proceeds from sale of stock | $ 63 | |
Number of shares issued (in shares) | 2,490,053 | |
Public offering price (in dollars per share) | $ 21.50 | |
Allocated public offering costs | $ 0.4 | |
First follow-on public offering and secondary offering | ||
Subsidiary, Sale of Stock [Line Items] | ||
Number of shares in transaction, including shares in secondary offering (in shares) | 4,300,000 | |
Underwriters option | ||
Subsidiary, Sale of Stock [Line Items] | ||
Number of shares issued (in shares) | 478,507 | 645,000 |
Secondary offering by selling shareholders | ||
Subsidiary, Sale of Stock [Line Items] | ||
Number of shares issued (in shares) | 190,053 | |
Public offering price (in dollars per share) | $ 22 | |
Allocated public offering costs | $ 0.2 | |
Second follow-on public offering | ||
Subsidiary, Sale of Stock [Line Items] | ||
Net proceeds from sale of stock | $ 71.6 | |
Number of shares in transaction, including shares in secondary offering (in shares) | 3,000,000 | |
Public offering price (in dollars per share) | $ 22 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Segments (Details) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021USD ($)segment | Dec. 31, 2020USD ($) | |
Accounting Policies [Abstract] | ||
Number of reportable segments | segment | 1 | |
Number of operating segments | segment | 1 | |
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 90,152 | $ 73,387 |
United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 82,739 | 68,118 |
International | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 7,413 | $ 5,269 |
Summary of Accounting Policies
Summary of Accounting Policies - Accounts Receivable and Allowance for Credit Losses (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | ||
Balance at beginning of year | $ 263 | $ 238 |
Provision | 14 | 234 |
Write-offs | (13) | (209) |
Balance at end of year | $ 264 | $ 263 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Property and Equipment (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Computer and office equipment | Minimum | |
Property, Plant and Equipment [Line Items] | |
Estimated useful life | 3 years |
Computer and office equipment | Maximum | |
Property, Plant and Equipment [Line Items] | |
Estimated useful life | 5 years |
Machinery and equipment | Minimum | |
Property, Plant and Equipment [Line Items] | |
Estimated useful life | 3 years |
Machinery and equipment | Maximum | |
Property, Plant and Equipment [Line Items] | |
Estimated useful life | 5 years |
Furniture and fixtures | |
Property, Plant and Equipment [Line Items] | |
Estimated useful life | 7 years |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||
Impairment losses on long-lived assets | $ 0 | $ 0 |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Revenue Recognition (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Minimum | |
Disaggregation of Revenue [Line Items] | |
Standard payment terms per agreements (in days) | 30 days |
Maximum | |
Disaggregation of Revenue [Line Items] | |
Standard payment terms per agreements (in days) | 90 days |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies - Warranty Program (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Warranty term (in years) | 1 year |
Sales credit reserve term (in years) | 1 year |
Summary of Significant Accoun_9
Summary of Significant Accounting Policies - Advertising Expenditures (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||
Advertising expenses | $ 1.2 | $ 0.3 |
Summary of Accounting Policie_2
Summary of Accounting Policies - Recently Adopted Accounting Standards (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Jan. 01, 2021 | Dec. 31, 2020 |
Accounting Policies [Abstract] | |||
Total operating lease liabilities | $ 5,505 | $ 3,800 | |
Operating lease right-of-use assets | $ 5,248 | 3,500 | $ 0 |
Deferred rent liabilities | $ 300 |
Marketable Securities (Details)
Marketable Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Cash equivalents | ||
Carrying Value | $ 57,829 | $ 47,348 |
Short-term investments | ||
Amortized Cost | 83,595 | 142,856 |
Unrealized Gains | 4 | 8 |
Unrealized Losses | (39) | (13) |
Aggregate Fair Value | 83,560 | 142,851 |
Total marketable securities, Amortized Cost | 141,424 | 190,204 |
Total marketable securities, Unrealized Gains | 4 | 8 |
Total marketable securities, Unrealized Losses | (39) | (13) |
Total marketable securities, Aggregate Fair Value | 141,389 | 190,199 |
Interest receivable | 300 | |
Money market funds | ||
Cash equivalents | ||
Carrying Value | 57,829 | 45,948 |
U.S. treasury securities | ||
Short-term investments | ||
Amortized Cost | 28,064 | 74,779 |
Unrealized Gains | 0 | 4 |
Unrealized Losses | (16) | (7) |
Aggregate Fair Value | 28,048 | 74,776 |
Corporate bonds | ||
Short-term investments | ||
Amortized Cost | 31,558 | 8,940 |
Unrealized Gains | 4 | 4 |
Unrealized Losses | (23) | (6) |
Aggregate Fair Value | 31,539 | 8,938 |
Commercial paper | ||
Cash equivalents | ||
Carrying Value | 1,400 | |
Short-term investments | ||
Amortized Cost | 23,973 | 59,137 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | 0 | 0 |
Aggregate Fair Value | $ 23,973 | $ 59,137 |
Fair Value Measurement - Market
Fair Value Measurement - Marketable Securities Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Marketable securities | ||
Marketable securities | $ 141,389 | $ 190,199 |
Money market funds | ||
Marketable securities | ||
Marketable securities | 57,829 | 45,948 |
U.S. treasury securities | ||
Marketable securities | ||
Marketable securities | 28,048 | 74,776 |
Corporate bonds | ||
Marketable securities | ||
Marketable securities | 31,539 | 8,938 |
Commercial paper | ||
Marketable securities | ||
Marketable securities | 23,973 | 60,537 |
Level 1 | ||
Marketable securities | ||
Marketable securities | 85,877 | 120,724 |
Level 1 | Money market funds | ||
Marketable securities | ||
Marketable securities | 57,829 | 45,948 |
Level 1 | U.S. treasury securities | ||
Marketable securities | ||
Marketable securities | 28,048 | 74,776 |
Level 1 | Corporate bonds | ||
Marketable securities | ||
Marketable securities | 0 | 0 |
Level 1 | Commercial paper | ||
Marketable securities | ||
Marketable securities | 0 | 0 |
Level 2 | ||
Marketable securities | ||
Marketable securities | 55,512 | 69,475 |
Level 2 | Money market funds | ||
Marketable securities | ||
Marketable securities | 0 | 0 |
Level 2 | U.S. treasury securities | ||
Marketable securities | ||
Marketable securities | 0 | 0 |
Level 2 | Corporate bonds | ||
Marketable securities | ||
Marketable securities | 31,539 | 8,938 |
Level 2 | Commercial paper | ||
Marketable securities | ||
Marketable securities | 23,973 | 60,537 |
Level 3 | ||
Marketable securities | ||
Marketable securities | 0 | 0 |
Level 3 | Money market funds | ||
Marketable securities | ||
Marketable securities | 0 | 0 |
Level 3 | U.S. treasury securities | ||
Marketable securities | ||
Marketable securities | 0 | 0 |
Level 3 | Corporate bonds | ||
Marketable securities | ||
Marketable securities | 0 | 0 |
Level 3 | Commercial paper | ||
Marketable securities | ||
Marketable securities | $ 0 | $ 0 |
Balance Sheet Components - Prop
Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Property and Equipment, Net | ||
Property and equipment, gross | $ 15,958 | $ 9,484 |
Less: Accumulated depreciation and amortization | (6,966) | (4,957) |
Property and equipment, net | 8,992 | 4,527 |
Depreciation expense | 2,100 | 1,100 |
Machinery and equipment | ||
Property and Equipment, Net | ||
Property and equipment, gross | 10,573 | 6,342 |
Construction in progress | ||
Property and Equipment, Net | ||
Property and equipment, gross | 3,657 | 1,692 |
Construction in Progress, Surgical Placement Instrument Set | ||
Property and Equipment, Net | ||
Property and equipment, gross | 3,300 | |
Construction in Progress, Santa Clara Lease | ||
Property and Equipment, Net | ||
Property and equipment, gross | 400 | |
Computer and office equipment | ||
Property and Equipment, Net | ||
Property and equipment, gross | 916 | 714 |
Leasehold improvements | ||
Property and Equipment, Net | ||
Property and equipment, gross | 503 | 503 |
Furniture and fixtures | ||
Property and Equipment, Net | ||
Property and equipment, gross | $ 309 | $ 233 |
Balance Sheet Components - Accr
Balance Sheet Components - Accrued Liabilities and Other (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Accrued Liabilities and Other | ||
Accrued compensation and related expenses | $ 10,055 | $ 9,175 |
Accrued professional services | 995 | 511 |
Others | 1,303 | 513 |
Accrued liabilities and other | $ 12,353 | $ 10,199 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) | 12 Months Ended | ||
Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Aug. 31, 2021ft²renewal_option | |
Operating Leased Assets [Line Items] | |||
Operating lease, term of written notice for termination | six months | ||
Area of property (sq ft) | ft² | 19,534 | ||
Lease renewal, number of options to renew | renewal_option | 1 | ||
Option lease renewal term | 3 years | ||
Rent expense | $ 1,200,000 | ||
Purchase commitments related to inventory | $ 1,200,000 | $ 300,000 | |
Indemnification Agreement | |||
Operating Leased Assets [Line Items] | |||
Costs to defend lawsuits or settle claims | 0 | ||
Costs accrued to defend lawsuits | $ 0 |
Commitment and Contingencies- S
Commitment and Contingencies- Schedule of Lease Costs (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | |
Operating lease expense | $ 1,181 |
Variable lease expense | 266 |
Total lease expense | 1,447 |
Cash paid for amounts included in the measurement of operating lease liabilities | 1,225 |
Leased assets obtained in exchange for new operating lease liabilities | $ 2,896 |
Weighted average remaining lease term (in years) | 3 years 11 months 23 days |
Weighted average discount rate | 5.75% |
Commitments and Contingencies_2
Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Jan. 01, 2021 | Dec. 31, 2020 |
Aggregate Future Minimum Lease Payments, After Adoption of ASC 842 | |||
2022 | $ 1,620 | ||
2023 | 1,544 | ||
2024 | 1,491 | ||
2025 | 990 | ||
2026 | 531 | ||
Thereafter | 10 | ||
Total operating lease payments | 6,186 | ||
Less: imputed interest | (681) | ||
Total operating lease liabilities | $ 5,505 | $ 3,800 | |
Aggregate Future Minimum Lease Payments, Prior to Adoption of ASC 842 | |||
2021 | $ 1,081 | ||
2022 | 1,001 | ||
2023 | 908 | ||
2024 | 893 | ||
2025 | 381 | ||
Thereafter | 24 | ||
Total | $ 4,288 |
Borrowings - Summary of Borrowi
Borrowings - Summary of Borrowings (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Disclosure [Abstract] | ||
Principal outstanding and final fee | $ 35,700 | $ 41,000 |
Less: Unamortized debt issuance costs | (100) | (661) |
Less: Unaccreted value of final fee | (627) | (884) |
Outstanding debt, net of debt issuance costs and unaccreted value of final fee | 34,973 | 39,455 |
Long-term borrowings | $ 34,973 | $ 39,455 |
Borrowings - Narrative (Details
Borrowings - Narrative (Details) - USD ($) $ in Thousands | Aug. 12, 2021 | May 29, 2020 | Apr. 21, 2020 | Oct. 31, 2017 | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Instrument [Line Items] | |||||||
Proceeds from debt financing | $ 35,000 | $ 45,297 | |||||
Final fee | $ 627 | 627 | 884 | ||||
Deferred liability for social security taxes, CARES Act | 1,000 | ||||||
Accrued liabilities | |||||||
Debt Instrument [Line Items] | |||||||
Deferred liability for social security taxes, CARES Act | 500 | 500 | 500 | ||||
Other long-term liabilities | |||||||
Debt Instrument [Line Items] | |||||||
Deferred liability for social security taxes, CARES Act | 500 | $ 500 | $ 500 | ||||
PPP Loan, CARES Act | |||||||
Debt Instrument [Line Items] | |||||||
Proceeds from PPP loan | $ 5,300 | ||||||
Term Loan | Pharmakon Term Loan | |||||||
Debt Instrument [Line Items] | |||||||
Proceeds from debt financing | $ 40,000 | ||||||
Debt period payment, interest only period | 35 months | ||||||
Fixed interest rate (percent) | 11.50% | ||||||
Effective interest rate during the period (percent) | 12.40% | ||||||
Term Loan | Pharmakon Term Loan | Prepayment Penalty, 31-48 Months | |||||||
Debt Instrument [Line Items] | |||||||
Debt prepayment penalty percentage (percent) | 2.00% | ||||||
Term Loan | Pharmakon Term Loan | Prepayment Penalty, 49-60 Months | |||||||
Debt Instrument [Line Items] | |||||||
Debt prepayment penalty percentage (percent) | 1.00% | ||||||
Term Loan | Solar Loan And Security Agreement | |||||||
Debt Instrument [Line Items] | |||||||
Fixed interest rate (percent) | 9.40% | ||||||
Aggregate principal amount | $ 40,000 | ||||||
Debt issuance costs | 800 | ||||||
Unamortized debt issuance costs | $ 700 | ||||||
Prepayment penalty and lender fees on debt extinguishment | $ 800 | ||||||
Allowable prepayment increments per agreement | $ 10,000 | ||||||
Prepayment premium in year one (percent) | 3.00% | ||||||
Prepayment premium in year two (percent) | 1.25% | ||||||
Prepayment premium in year three or later (percent) | 0.50% | ||||||
Final fee | $ 1,000 | ||||||
Final fee as percentage of aggregate principal amount (percent) | 2.50% | ||||||
Effective interest rate during the period (percent) | 10.30% | 10.60% | |||||
Term Loan | Solar Loan And Security Agreement | Variable Option One | |||||||
Debt Instrument [Line Items] | |||||||
Debt period payment, interest only period | 36 months | ||||||
Basis spread on variable rate (percent) | 0.33% | ||||||
Term Loan | SVB Term Loan | |||||||
Debt Instrument [Line Items] | |||||||
Fixed interest rate (percent) | 5.75% | ||||||
Aggregate principal amount | $ 35,000 | ||||||
Debt issuance costs | 100 | $ 100 | |||||
Unamortized debt issuance costs | 1,300 | 1,300 | |||||
Prepayment penalty and lender fees on debt extinguishment | $ 500 | $ 500 | |||||
Basis spread on variable rate (percent) | 2.50% | ||||||
Final fee | $ 700 | ||||||
Final fee as percentage of aggregate principal amount (percent) | 2.00% | ||||||
Effective interest rate during the period (percent) | 6.30% | ||||||
Term Loan | SVB Term Loan | Prepayment Penalty, 1-24 Months | |||||||
Debt Instrument [Line Items] | |||||||
Debt prepayment penalty percentage (percent) | 1.00% | ||||||
Term Loan | SVB Term Loan | Prepayment Penalty, 24 Months On | |||||||
Debt Instrument [Line Items] | |||||||
Debt prepayment penalty percentage (percent) | 0.00% |
Borrowings - Annual Future Mini
Borrowings - Annual Future Minimum Principal Payments (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Maturities of Long-term Debt [Abstract] | ||
2022 | $ 0 | |
2023 | 7,292 | |
2024 | 17,500 | |
2025 | 10,908 | |
2026 | 0 | |
Total principal and final fee payments | $ 35,700 | $ 41,000 |
Warrants - Issued and Outstandi
Warrants - Issued and Outstanding (Details) - Common Stock - USD ($) $ / shares in Units, $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Warrants Issued 3/1/2017 | ||
Class of Warrant or Right [Line Items] | ||
Number of Shares Underlying Warrants (in shares) | 1,388 | 1,388 |
Price per Share (in dollars per share) | $ 5.94 | $ 5.94 |
Fair Value | $ 5 | $ 5 |
Warrants Issued 7/22/2013 | ||
Class of Warrant or Right [Line Items] | ||
Number of Shares Underlying Warrants (in shares) | 32,983 | 32,983 |
Price per Share (in dollars per share) | $ 9.10 | $ 9.10 |
Fair Value | $ 122 | $ 122 |
Warrants Issued 11/26/2014 | ||
Class of Warrant or Right [Line Items] | ||
Number of Shares Underlying Warrants (in shares) | 6,680 | 6,680 |
Price per Share (in dollars per share) | $ 16.47 | $ 16.47 |
Fair Value | $ 49 | $ 49 |
Warrants Issued 10/20/2015 | ||
Class of Warrant or Right [Line Items] | ||
Number of Shares Underlying Warrants (in shares) | 41,650 | 41,650 |
Price per Share (in dollars per share) | $ 16.47 | $ 16.47 |
Fair Value | $ 396 | $ 396 |
Warrants Issued 11/9/2015 | ||
Class of Warrant or Right [Line Items] | ||
Number of Shares Underlying Warrants (in shares) | 25,709 | 25,709 |
Price per Share (in dollars per share) | $ 16.47 | $ 16.47 |
Fair Value | $ 244 | $ 244 |
Warrants Issued 12/22/2016 | ||
Class of Warrant or Right [Line Items] | ||
Number of Shares Underlying Warrants (in shares) | 9,712 | 9,712 |
Price per Share (in dollars per share) | $ 10.03 | $ 10.03 |
Fair Value | $ 45 | $ 45 |
Common Stock Warrants | ||
Class of Warrant or Right [Line Items] | ||
Number of Shares Underlying Warrants (in shares) | 118,122 | 118,122 |
Fair Value | $ 861 | $ 861 |
Common and Preferred Stock - Na
Common and Preferred Stock - Narrative (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | ||
Common stock authorized (in shares) | 100,000,000 | 100,000,000 |
Preferred stock authorized (in shares) | 5,000,000 | 5,000,000 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock issued (in shares) | 33,674,085 | 32,583,220 |
Common stock outstanding (in shares) | 33,674,085 | 32,583,220 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock issued (in shares) | 0 | 0 |
Preferred stock outstanding (in shares) | 0 | 0 |
Common stock, dividends declared (in dollars per share) | $ 0 |
Stock-Based Compensation - Narr
Stock-Based Compensation - Narrative (Details) $ in Thousands | Jan. 01, 2022shares | Apr. 30, 2020 | Dec. 31, 2020USD ($)renewal_optionshares | Dec. 31, 2021USD ($)shares | Dec. 31, 2020USD ($)shares |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Aggregate intrinsic value of options exercised | $ 8,100 | $ 5,600 | |||
Options granted (in shares) | shares | 0 | 26,236 | |||
Unrecognized compensation costs | $ 1,400 | ||||
Early exercise of stock options, share subject to repurchase (in shares) | shares | 5,836 | 0 | 5,836 | ||
Issuance of common stock related to employee stock purchase plan (in shares) | shares | 147,295 | 137,377 | |||
Issuance of common stock related to employee stock purchase plan | $ 2,343 | $ 1,915 | |||
Stock-based compensation expense | $ 16,866 | 11,927 | |||
Minimum | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Exercise price of option as percent of fair market value when individual owns more than 10% of shares outstanding (percent) | 110.00% | ||||
Stock Options | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Percentage of ownership of outstanding shares for alternate terms | 10.00% | ||||
Stock option term (in years) | 10 years | ||||
Stock option term when grantee holds more than 10% of shares outstanding (in years) | 5 years | ||||
Award vesting period (in years) | 4 years | ||||
Unrecognized compensation cost, expected period for recognition (in years) | 1 year | ||||
Incentive Stock Options | Minimum | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Exercise price of option as percent of fair market value (percent) | 100.00% | ||||
Nonqualified Stock Options | Minimum | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Exercise price of option as percent of fair market value (percent) | 85.00% | ||||
Restricted Stock Units | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Unrecognized compensation cost, expected period for recognition (in years) | 2 years 8 months 12 days | ||||
Unrecognized compensation cost | $ 32,600 | ||||
Restricted Stock Units | Minimum | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Award vesting period (in years) | 2 years | ||||
Restricted Stock Units | Maximum | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Award vesting period (in years) | 4 years | ||||
2018 Equity Incentive Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Annual increase in shares reserved as percentage of prior year-end shares outstanding (percent) | 5.00% | ||||
Shares available for future grants (in shares) | shares | 3,520,102 | ||||
2018 Equity Incentive Plan | Subsequent Event | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Increase in number of shares reserved for future issuance (in shares) | shares | 1,683,704 | ||||
2018 ESPP | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Unrecognized compensation cost | $ 300 | ||||
Purchase price of common stock as a percent of fair market value (percent) | 85.00% | ||||
Employees stock purchase program offering period interval (in months) | 6 months | 12 months | |||
Number of purchase periods in offering interval | renewal_option | 2 | ||||
Number of shares reserved for issuance (in shares) | shares | 884,155 | ||||
Accrued compensation and related expenses for employee payroll deductions | $ 400 | $ 300 | 400 | ||
Stock-based compensation expense | $ 800 | $ 1,200 | |||
2018 ESPP | Subsequent Event | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Increase in number of shares reserved for future issuance (in shares) | shares | 336,741 |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Number of Shares | ||
Beginning balance (in shares) | 2,405,957 | 2,718,971 |
Options granted (in shares) | 0 | 26,236 |
Options exercised (in shares) | (369,375) | (323,701) |
Options canceled and forfeited (in shares) | (27,069) | (15,549) |
Ending balance (in shares) | 2,009,513 | 2,405,957 |
Options vested and exercisable (in shares) | 1,870,352 | |
Options vested and expected to vest (in shares) | 2,031,988 | |
Weighted-Average Exercise Price | ||
Beginning balance (in dollars per share) | $ 8.54 | $ 8.02 |
Options granted (in dollars per share) | 17.31 | |
Options exercised (in dollars per share) | 6.94 | 4.52 |
Options canceled and forfeited (in dollars per share) | 15.85 | 17.07 |
Ending balance (in dollars per share) | 8.73 | $ 8.54 |
Options vested and exercisable (in dollars per share) | 7.81 | |
Options vested and expected to vest (in dollars per share) | $ 8.61 | |
Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value | ||
Weighted-average remaining contractual life, options outstanding (in years) | 4 years 10 months 24 days | |
Weighted-average remaining contractual life, options vested and exercisable (in years) | 4 years 8 months 23 days | |
Weighted-average remaining contractual life, options vested and expected to vest (in years) | 5 years 1 month 13 days | |
Aggregate intrinsic value, options outstanding | $ 27,089 | |
Aggregate intrinsic value, options vested and exercisable | 26,933 | |
Aggregate intrinsic value, options vested and expected to vest | $ 27,633 |
Stock-Based Compensation - Outs
Stock-Based Compensation - Outstanding Options and Exercisable Options Information by Range of Exercise Prices (Details) | 12 Months Ended |
Dec. 31, 2021$ / sharesshares | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Options outstanding, number of shares (in shares) | shares | 2,009,513 |
Options outstanding, average remaining contractual life (years) | 4 years 10 months 24 days |
Options outstanding, weighted-average exercise price (in dollars per share) | $ 8.73 |
Options vested and exercisable, number of shares (in shares) | shares | 1,870,352 |
Options vested and exercisable, weighted-average exercise price (in dollars per share) | $ 7.81 |
$0.84-$3.69 | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Exercise price, lower limit (in dollars per share) | 2.11 |
Exercise price, upper limit (in dollars per share) | $ 3.69 |
Options outstanding, number of shares (in shares) | shares | 405,476 |
Options outstanding, average remaining contractual life (years) | 2 years 5 months 12 days |
Options outstanding, weighted-average exercise price (in dollars per share) | $ 3.36 |
Options vested and exercisable, number of shares (in shares) | shares | 405,476 |
Options vested and exercisable, weighted-average exercise price (in dollars per share) | $ 3.36 |
$3.70-$4.41 | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Exercise price, lower limit (in dollars per share) | 3.70 |
Exercise price, upper limit (in dollars per share) | $ 4.41 |
Options outstanding, number of shares (in shares) | shares | 517,272 |
Options outstanding, average remaining contractual life (years) | 3 years 11 months 23 days |
Options outstanding, weighted-average exercise price (in dollars per share) | $ 4.30 |
Options vested and exercisable, number of shares (in shares) | shares | 517,272 |
Options vested and exercisable, weighted-average exercise price (in dollars per share) | $ 4.30 |
$4.42-$5.31 | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Exercise price, lower limit (in dollars per share) | 4.42 |
Exercise price, upper limit (in dollars per share) | $ 5.31 |
Options outstanding, number of shares (in shares) | shares | 423,154 |
Options outstanding, average remaining contractual life (years) | 5 years 4 months 9 days |
Options outstanding, weighted-average exercise price (in dollars per share) | $ 4.67 |
Options vested and exercisable, number of shares (in shares) | shares | 421,812 |
Options vested and exercisable, weighted-average exercise price (in dollars per share) | $ 4.67 |
$5.32-$20.51 | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Exercise price, lower limit (in dollars per share) | 5.32 |
Exercise price, upper limit (in dollars per share) | $ 20.51 |
Options outstanding, number of shares (in shares) | shares | 254,817 |
Options outstanding, average remaining contractual life (years) | 6 years 5 months 8 days |
Options outstanding, weighted-average exercise price (in dollars per share) | $ 11.71 |
Options vested and exercisable, number of shares (in shares) | shares | 235,053 |
Options vested and exercisable, weighted-average exercise price (in dollars per share) | $ 11.29 |
$20.52-$22.00 | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Exercise price, lower limit (in dollars per share) | 20.52 |
Exercise price, upper limit (in dollars per share) | $ 22 |
Options outstanding, number of shares (in shares) | shares | 408,794 |
Options outstanding, average remaining contractual life (years) | 7 years 14 days |
Options outstanding, weighted-average exercise price (in dollars per share) | $ 22 |
Options vested and exercisable, number of shares (in shares) | shares | 290,739 |
Options vested and exercisable, weighted-average exercise price (in dollars per share) | $ 22 |
Stock-Based Compensation - Valu
Stock-Based Compensation - Valuation Assumptions for Stock Options (Details) - Stock Options - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Black-Scholes option-pricing model assumptions | ||
Weighted-average grant date fair value of options granted (in dollars per share) | $ 8.16 | |
Expected volatility, minimum (percent) | 46.70% | |
Expected volatility, maximum (percent) | 47.20% | |
Risk-free interest rate, minimum (percent) | 1.60% | |
Risk-free interest rate, maximum (percent) | 1.60% | |
Dividend yield (percent) | 0.00% | |
Minimum | ||
Black-Scholes option-pricing model assumptions | ||
Expected term (in years) | 5 years 6 months | |
Maximum | ||
Black-Scholes option-pricing model assumptions | ||
Expected term (in years) | 7 years |
Stock-Based Compensation - Rest
Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Number of Shares | ||
Beginning balance (in shares) | 1,165,295 | 543,041 |
Granted (in shares) | 1,187,143 | 1,016,432 |
Vested (in shares) | (574,195) | (344,779) |
Canceled and forfeited (in shares) | (211,721) | (49,399) |
Ending balance (in shares) | 1,566,522 | 1,165,295 |
Weighted- Average Grant Date Fair Value | ||
Beginning balance (in dollars per share) | $ 20.07 | $ 19.72 |
Granted (in dollars per share) | 28.46 | 20.17 |
Vested (in dollars per share) | 21.76 | 19.87 |
Canceled and forfeited (in dollars per share) | 24.76 | 19.73 |
Ending balance (in dollars per share) | $ 25.17 | $ 20.07 |
Stock-Based Compensation - Va_2
Stock-Based Compensation - Valuation Assumptions for ESPP Purchase Rights (Details) - ESPP Purchase Rights | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term (in years) | 6 months | |
Expected volatility, minimum (percent) | 48.80% | 38.30% |
Expected volatility, maximum (percent) | 49.50% | 79.40% |
Risk-free interest rate, minimum (percent) | 0.04% | 0.10% |
Risk-free interest rate, maximum (percent) | 0.07% | 1.60% |
Dividend yield (percent) | 0.00% | 0.00% |
Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term (in years) | 6 months | |
Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term (in years) | 1 year |
Stock-Based Compensation - St_2
Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 16,866 | $ 11,927 |
Cost of goods sold | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | 530 | 331 |
Sales and marketing | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | 8,448 | 5,527 |
Research and development | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | 1,710 | 1,139 |
General and administrative | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 6,178 | $ 4,930 |
Employee Benefit Plan (Details)
Employee Benefit Plan (Details) - 401(k) Plan - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Defined Contribution Plan Disclosure [Line Items] | ||
Employer matching contribution, percentage of eligible compensation | 3.00% | |
Employer matching contribution, maximum amount per employee | $ 1,000 | |
Employer contributions | $ 200,000 |
Net Loss Per Share of Common _3
Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Earnings Per Share [Abstract] | ||
Net loss | $ (56,572) | $ (43,697) |
Weighted-average number of common shares used to compute basic and diluted net loss per share (in shares) | 33,145,930 | 29,059,171 |
Net loss per share, basic (in USD per share) | $ (1.71) | $ (1.50) |
Net loss per share, diluted (in USD per share) | $ (1.71) | $ (1.50) |
Net Loss Per Share of Common _4
Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock equivalents excluded from the computation of diluted net loss per share | 3,755,421 | 3,778,250 |
Stock options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock equivalents excluded from the computation of diluted net loss per share | 2,009,513 | 2,405,957 |
Restricted stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock equivalents excluded from the computation of diluted net loss per share | 1,566,522 | 1,165,295 |
Shares subject to repurchase | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock equivalents excluded from the computation of diluted net loss per share | 0 | 5,836 |
ESPP purchase rights | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock equivalents excluded from the computation of diluted net loss per share | 61,264 | 83,040 |
Common stock warrants | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock equivalents excluded from the computation of diluted net loss per share | 118,122 | 118,122 |
Income Taxes - Components of Lo
Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Components of loss before income taxes | ||
Domestic | $ (57,035) | $ (41,708) |
Foreign | 463 | (1,989) |
Net loss | $ (56,572) | $ (43,697) |
Income Taxes - Components of De
Income Taxes - Components of Deferred Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Deferred tax expense: | ||
Federal | $ 12,994 | $ 9,855 |
State | 1,878 | 2,711 |
Foreign | 461 | 583 |
Total deferred income taxes | 15,333 | 13,149 |
Change in deferred tax valuation allowance | (15,333) | (13,149) |
Net deferred income tax | $ 0 | $ 0 |
Income Taxes - Reconciliation o
Income Taxes - Reconciliation of Effective Income Tax Rate (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Effective Income Tax Rate Reconciliation | ||
Tax at statutory federal rate (percent) | (21.00%) | (21.00%) |
State tax, net of federal benefit (percent) | (3.30%) | (6.20%) |
Tax credits (percent) | (0.80%) | (0.70%) |
Change in deferred tax valuation allowance (percent) | 27.10% | 30.10% |
Stock compensation (percent) | (1.70%) | (1.20%) |
Foreign rate differences (percent) | 0.10% | (1.30%) |
Other (percent) | (0.40%) | 0.30% |
Total income tax expense (percent) | 0.00% | 0.00% |
Income Taxes - Temporary Differ
Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Deferred Tax Assets | |||
Net operating loss carryforwards | $ 66,015 | $ 52,331 | |
Research and development credits | 3,837 | 3,160 | |
Accruals and reserves | 1,994 | 2,669 | |
Interest limitation | 3,995 | 2,781 | |
Stock compensation | 2,728 | 2,395 | |
Depreciation and amortization | 152 | 117 | |
Operating lease liabilities | 1,376 | 0 | |
Total deferred tax assets | 80,097 | 63,453 | |
Operating lease right-of-use assets | (1,311) | 0 | |
Total deferred tax liabilities | (1,311) | 0 | |
Less: Valuation allowance | (78,786) | (63,453) | $ (50,304) |
Total deferred tax asset, net of valuation allowance | $ 0 | $ 0 |
Income Taxes - Changes in Valua
Income Taxes - Changes in Valuation Allowance (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Changes in Valuation Allowance | ||
Valuation allowance, beginning balance | $ 63,453 | $ 50,304 |
Additions during the period | 15,333 | 13,149 |
Valuation allowance, ending balance | $ 78,786 | $ 63,453 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Income Tax Disclosure [Line Items] | ||
Limited net operating loss carryforwards | $ 1,400,000 | |
Deferred liability for social security taxes, CARES Act | $ 1,000,000 | |
Accrued interest related to unrecognized tax benefits | 0 | $ 0 |
Federal | ||
Income Tax Disclosure [Line Items] | ||
Net operating loss carryforwards | 255,500,000 | |
Credit carryforwards | 3,200,000 | |
State | ||
Income Tax Disclosure [Line Items] | ||
Net operating loss carryforwards | 203,200,000 | |
Credit carryforwards | $ 2,900,000 |
Income Taxes - Uncertain Income
Income Taxes - Uncertain Income Tax Positions (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Uncertain income tax positions [Roll Forward] | ||
Balance at beginning of the year | $ 1,513 | $ 1,287 |
Increases related to tax positions taken prior to current year | 817 | 0 |
Increases related to current year's tax positions | 325 | 226 |
Balance at end of the year | $ 2,655 | $ 1,513 |
Related Party Transactions (Det
Related Party Transactions (Details) - SeaSpine - Joint development agreement - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Related Party Transaction [Line Items] | ||
Reimbursement charges expensed | $ 29,000 | $ 118,000 |
Outstanding liability to SeaSpine | $ 0 | |
Term of product royalty sales period (in years) | 10 years |